Etude 2012-VInteractive FranceBiotech

Embed Size (px)

Citation preview

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    1/35

    Sindrili df tgo Fronbg

    @hfo Rbhonbos Hneustry=39=

    99tg Oehthdn

    b

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    2/35

    Oehtdrhi`

    go @hfo Rbhonbos sob

    tdr gis tdeiy mobdlo

    i lirjot roi`hty, ropro

    sonthnk i rosorvdhr df hnndvi

    thdn ine krdwtg. Hneooe, ht hs

    ehffhbu`t td fu``y onvhshdn tgo

    sbdpo df hlpibt tgit tgo @hfo

    Rbhonbos wh`` mrhnk td dur hvos

    dvor tgo noxt =3 yoirs. Hn

    Frinbo, eosphto tgo brhshs, tghs

    hneustry gis prdkrossoe shknh

    fhbint`y dvor tgo pist 9? yoirs

    ine gis roibgoe i stiko df

    liturhty tgit hs rof`obtoe hn

    tgo rosu`ts df dur stuey.

    Frinbo Mhdtobg gis moon it

    tgo fdrofrdnt df tghs olor

    konbo df @hfo Rbhonbos hn

    Frinbo, suppdrthnk tgo krdwtg

    df in hneustry tgit hnb`ueos

    mhdtobg, loetobg ine b`oin

    tobg bdlpinhos. My wiy df

    dur liny bdnstrubthvo prdpd

    si`s ine robdlloneithdns

    eo`hvoroe td tgo kdvornlont,wo givo go`poe konorito i

    eynilhb sobtdr hn wghbg ro

    soirbg ine eovo`dplont iro

    tgo erhvhnk fdrbos df obdnd

    lhb krdwtg ine, is i bdnso

    quonbo, df oxpdrts.

    Ugo @hfo Rbhonbos hneustry hn

    Frinbo ehsthnkuhsgos htso`f my

    i eynilhb fhninbhi` lirjot

    tgit hnvosts hn, ini`yzos ine

    suppdrts hts sustihnim`o eo

    vo`dplont. Ugo liny ydunk

    bdlpinhos tgit lijo up tghs

    sobtdr bdlmhno td litbg i

    `irko pgirlibouthbi` bdl

    piny hn liny loisuros, whtg

    tgo ieehthdni` bipibhty fdr

    eovo`dphnk ehsrupthvo tobgnd

    `dkhos ine tijhnk rhsjs.

    Ugo nirrdw prhsl tgrdukg

    wghbg dur pum`hb iutgdrhthos

    ine hneustry `oieors soo dur

    ydunk hnndvithvo bdlpinhos

    tihnts tgo eovo`dplont df dur

    `oieors df tdldrrdw. Rli``

    ine lheshzo ontorprhsos

    'SLOs( iro sth`` dn`y soon is

    i supp`hor dr sumbdntribtdr

    fdr i `irko krdup. Ht hs thlo tdrobdknhzo tgo guko pdtonthi`

    tgit rosheos hn dur sli`` hn

    ndvithvo bdlpinhos. Ht hs thlo

    td put hn p`ibo tgo nobossiry

    `okhs`ithvo loisuros td fur

    tgor onbduriko tgohr krdwtg.

    Adms, oxpdrts ine obdndlhb

    krdwtg wh`` fd``dw ine tgo

    monofht wh`` mo bd``obthvo.

    Fhni``y, H wdu`e strdnk`y wirn

    dur `oieors df tgo einkor

    pdsoe my Frinbos toneonby

    td b`hp subbossfu` prdkrils

    ine sprhnj`o pdpu`hst loi

    suros hntd `okhs`ituro. Rubg

    ibthdns rhsj hlldmh`hzhnk tgo

    obdndly ine bin hneubo eo

    b`hno. [o nooe i pd`hthbi` wh``

    tgit hs fdbusoe dn suppdrthnk

    dur phdnoorhnk ydunk bdlpi

    nhos ine prdtobthnk tgol hn

    tgo hntornithdni` ironi.

    Iner Bgdu`hji

    Iner Bgdu`hjiSrosheont df Frinbo Mhdtobg,Bgihrlin ine BOD df Bo``obths

    U

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    3/35

    Lotgded`dky

    Sirt df tgo ini`yshs prosontoe hn tghs stuey hs misoe dn eiti

    bd``obtoe frdl Fronbg @hfo Rbhonbos bdlpinhos vhi i soburo

    dn`hno survoy p`itfdrl.

    Hn dreor td tijo pirt hn tgo survoy, i bdlpiny lust loot tgo

    fd``dwhnk tgroo brhtorhi1

    ` Mo ibthvo hn tgo @hfo Rbhonbos hneustry hn Frinbo

    I``dbito it oist 9?/ df tdti` oxponsos td ]osoirbg

    ine Eovo`dplont

    ` Givo `oss tgin =?3 olp`dyoos

    [gh`o tgo @hfo Rbhonbos sobtdr hn Frinbo gis fdr liny yoirs

    moon edlhnitoe my Sothto ot Ldyonno Ontroprhsos , tghs

    yoir siw tgo hnb`ushdn df tgroo bdlpinhos tgit robont`y

    krieuitoe frdl Sothto ot Ldyonno Ontroprhsos stitus td

    Ontroprhsos eo Uih``o Hntorlehihro stitus. Ugo tgrosgd`e df

    ]&E hnvostlont rolihns it 9?/ df tdti` oxponsos, tgo silo

    `ovo` roquhroe td kihn o`hkhmh`hty fdr tgo Xdunk Hnndvithvo

    Ontorprhso 'AOH( stitus hn Frinbo. Rhlh`ir td tgo =399 htorithdn,

    tghs yoirs survoy p`iboe in ieeoe olpgishs dn tgo hnbdrpd

    rithdn df i roprosontithvo silp`o df Loetobg ine B`ointobgbdlpinhos.

    Ugo rosu`ts df tgo survoy givo moon pum`hsgoe hn ikkrokito

    hn dreor td rospobt tgo bdnfheonthi`hty df rospdneonts.

    Ugo bdnvonthdni` eofhnhthdn df Mhdtobgnd`dky iedptoe my tgo

    DOBE hs Ugo ipp`hbithdn df sbhonbo ine tobgnd`dky td `hvhnk

    drkinhsls, is wo`` is pirts, prdeubts ine ldeo`s tgorodf, td

    i`tor `hvhnk dr ndn`hvhnk litorhi`s fdr tgo prdeubthdn df jndw

    `oeko, kddes ine sorvhbos.

    98= bdlpinhos eob`irhnk ibthvhthos hn tgo @hfo Rbhonbos

    pirthbhpitoe hn tgo o`obtrdnhb survoy ielhnhstoroe vhi Rpghnx

    sdftwiro frdl Fomruiry 95 td Iprh` 9? =392. ]ospdnsos frdl

    976 bdlpinhos woro rotihnoe fdr ini`yshs ine hnb`ushdn hn

    tgo Sindrili.

    Fhninbhi` eiti ine hnfdrlithdn rokirehnk pum`hb pd`hby prd

    krils woro bdlph`oe my Frinbo Mhdtobg stiff lolmors ushnk

    pum`hb rosdurbos ine tghrepirty eitimisos.

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    4/35

    Uim`o df Bdntonts

    ?

    HNU]DE_BUHDN

    Ghstdry df tgo Fronbg @hfo Rbhonbos Hneustry 36

    Joy Fhkuros fdr =39= 37

    Kodkripghbi` Ehstrhmuthdn 38

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

    Bdlpiny Rhzo ine Olp`dyoo Oeubithdn 93

    Bdlpiny Iko, Drhkhn ine Edlihn df Ibthvhty 99

    Bdlpiny Broithdns ine @hquheithdns 9=Oxport tosthldny1 Sgh`hppo Sdu`otty, LE 92

    Sirtnorsghps ine B`honts 95

    Oxport tosthldny1 Sgh`hppo Kdupht 9?

    Sitonts 96

    Oxport tosthldny1 Li`ys Forroro 9;

    Srdeubts 97

    F]INBO1 FHNINBHNK HNNDVIUHDN

    K`dmi` Sorspobthvo df Robtdr Funehnk =3

    _so df Sum`hb Lirjots =9

    Oxport tosthldny1 ]ifi`o Udrealin, LE ==

    Vonturo Biphti` =2

    Kdvornlont Ruppdrt =5

    Oxport tosthldny1 Siu`Frindhs Fdurnhor =?

    HNUO]NIUHDNI@ SO]RSOBUHVOR

    @hfo Rbhonbos Bdlpinhos dn tgo NXRO Ourdnoxt$I`tornoxt =7NXRO NOWU Mhdtobg Hneox =8

    Oxport tosthldny1 Berhb Ldroiu 23

    Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos 29

    INNOW

    @hst df Bdllorbhi`hzoe Srdeubts ine Sum`hb Bdlpinhos 2=

    @hst df 976 bdlpinhos pirthbhpithnk hn tgo stuey 22

    Oxghmht Hneox 25

    Imdut Frinbo Mhdtobg ine tgo Sindrili Rtuey 2?

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    5/35

    6

    HSD1 F`ilo` Uobgnd`dkhos 'Auno(

    HSD1 Borop 'Fomruiry(:Urinskono 'Lirbg(:Rti``orkonos 'Au`y(

    HSD1 Nhbdx 'Ndvolmor(

    Fdunehnk df Frinbo Mhdtobg

    Fdunehnk df @FM

    Fdunehnk df Konsot

    Fdunehnk df Biy`i

    Fdunehnk dfUrinskono

    Broithdn df tgo Ikonbo Nithdni`o eo i]obgorbgo 'IN](!:Broithdn df DROD:Broithdn df tgo Bdlpoththvhty MhdB`ustors

    Broithdn df HnndMhd, tgo spobhi`ty hnvostlontfune fdr Mhdtobg linikoe my BEB Ontroprhsos

    Broithdn df tgo Xdunk Hnndvithvo Bdlpiny 'AOH(eoshknithdn!

    98;;

    98;8

    9885

    9872

    9878

    =335

    9888

    9887

    988;

    9886

    =336

    =33;

    =337

    =338

    =33?

    Ghstdry df tgo Fronbg @hfo Rbhonbos Hneustry

    Broithdn df tgo ]osoirbgUix Broeht 'BH](

    Xoir

    98;;

    9873

    987=

    9875

    987;

    9878

    =33=

    Konsot 'F]( purbgisoe my Rordnd 'BG(

    Sisshnk df tgo UOSI @iw!'Iukust =33;(

    !robdlloneoe my Frinbo Mhdtobg

    Broithdn df tgo NXRO Ourdnoxt NOWU Mhdtobg Hneox!:Broithdn df tgo Rtritokhb Hnvostlont Fune 'FRH(:Broithdn df tgo Rtritokhb Hneustrhi` Hnndvithdn'HRH( fune it DROD!

    Sisshnk df tgo Hnndvithdn @iw 'Au`y 9888(, `oiehnk tdtgo broithdn df tgo Bdnbdurs Nithdni` eIheo `iBrithdn eOntroprhsos eo Uobgnd`dkhos Hnndvintos

    Broithdn df tgo Nduvoiu Lirbg stdbj oxbginko fdr stirtup bdlpinhos

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    6/35

    9

    ;

    =393

    =392Broithdn df mphfrinbo, tgo Fronbgpum`hb minj df hnvostlont

    ILL hssuoe td MhdI``hinbo Sgirli fdr RhtivhkHSD1 Rphnowiy 'Fomruiry(: Rphnokuire 'Iprh`(: Orytobg 'Iprh`(

    Oxdnght 'F]( purbgisos HnKon Mhdsbhonbos 'F]( ine mobdlosEhixdnght: Vhvi`hs 'F]( purbgisos Hntorbo`` 'I_( ine mobdlosVi`novi: Ndviki`h Sgirli 'F]( hs purbgisoe my Rinton Sgirlibouthbi`s 'AS(

    HSD1 Iedbhi 'Fomruiry(: ODR Hlikhnk 'Fomruiry(: Hntrisonso'Fomruiry(: EMV Uobgnd`dkhos 'Lirbg(: Nindmhdthx 'Dbtdmor(:Ndvibyt 'Dbtdmor(: Ugoriehik 'Eobolmor(

    Rindfh 'F]( purbgisos Konzylo '_R(: Hpsdkon hs purbgisoemy Yhikon 'N@( ine mobdlos Yhikon Lirsoh``o: Bo``obths 'F](purbgisos Bo``irths 'RO(HSD1 Mhdsynox 'Lirbg(: Loehin Uobgnd`dkhos 'Liy(: K`dmi`Mhdonorkhos 'Auno(: Liuni Joi Uobgnd`dkhos 'Au`y(

    Bo``obths 'F]( purbgisos BytdSu`so Rbhonbos '_R(HSD1 IM Rbhonbo 'Iprh`(: Eohndvo 'Iprh`(: Nodvibs 'Iprh`(:Hntokrikon 'Auno(: Birlit 'Au`y(: Rtontys 'Dbtdmor(

    Rindfh 'F]( purbgisos Fdvoi Sgirlibouthbi`s 'F](:IstriQonobi '_J( purbgisos Ndvoxo` 'F](HSD1 Yuintul Kondlhbs 'Au`y(

    HSD1 Hpsdkon 'Auno(

    HSD1 Bo``obths 'Fomruiry(: Lotimd`hb Oxp`dror 'Iprh`(: Kondwiy 'Liy(:Vhvi`hs 'Auno(: Gymrhkonhbs 'Eobolmor(

    ILL hssuoe td MhdI``hinbo Sgirli fdr @drilybHSD1 Hnnito Sgirli 'Lirbg(: Konfht 'Eobolmor(

    HSD1 Oxdnght 'Ndvolmor(: MhdI``hinbo Sgirli 'Eobolmor(

    =39=

    Nulmor dfBdlpinhosFduneoe

    9889

    9882

    988?

    988;

    9888

    =339

    =332

    =33?

    =33;

    =338

    =399

    Ainuiry =399 1Eristhb ]ofdrl dftgo AOH eoshknithdn

    =399

    Ovd`uthdn df @hfo Rbhonbos Bdlpiny Broithdn hn Frinbo

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    7/35

    Frinbo1 Joy Fhkuros fdr =39=

    bdlpinhosstuehoe

    df bdlpinhos iro93* yoirs d`e

    bdlpinhosbroitoe hn =39=

    tdti` olp`dyoos'ivk df == por

    bdlpiny(

    bdllorbhi`hzoetgoripouthb prdeubts tgoripouthb prdeubtshn eovo`dplont ehikndsthb prdeubtshn eovo`dplont loehbi eovhboshn eovo`dplont

    pum`hb`y trieoebdlpinhos

    hn tdti`rovonuos

    hnvostoe hn ]osoirbgine Eovo`dplont

    osthlitoenot `dssos

    976 22/ 58 59?3

    =? =78 78 98

    26 =?9 L =87L =56L

    7

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    8/35

    8

    H`o,eo,Frinbo

    ??

    Mrotikno

    ;Siys eo`i @dhro

    99

    Sdhtdu,Bgirontos

    9

    Bontro

    9 Mdurkdkno2

    Bgilpikno,Ireonno

    9

    Shbireho

    =

    Ndre,Sis,

    eo,Bi`ihs

    Lheh,Syrnos

    92

    @inkuoedb,]dussh``dn

    9?

    Iquhtihno

    2

    MissoNdrlineho

    ]gno,I`pos

    2?

    @hldushn

    ? Iuvorkno

    ?

    Frinbgo,Bdlt

    9

    @drrihno

    =

    Srdvonbo,I`pos,Bto eIzur

    93

    Bdrso

    GiutoNdrlineho

    Kodkripghbi` Ehstrhmuthdn

    I`sibo

    >< 5?

    =2 5?

    9= =2

    0 9=

    ?

    2

    H`oeoFrinbo bdnthnuos td givo tgo ghkgost bdnbontrithdn df @hfo Rbhonbos bdlpinhos hn Frinbo, is i`ldst i

    tghre df tgo bdlpinhos rospdnehnk td tgo survoy iro goiequirtoroe hn tgo rokhdn. Ugo ]gnoI`pos rokhdnrotihns hts pdshthdn is tgo sobdne irkost bontor df ibthvhty hn Frinbo. Ughs yoirs silp`o wis ehsthnkuhsgoe mystrdnk @hfo Rbhonbos roprosontithdn hn tgo sdutgorn rokhdns dfSIBI, @inkuoedb]dussh``dn ine LhehSyrnos.Ldst hlpdrtint`y, i goi`tgy ehstrhmuthdn df bdlpiny hlp`intithdn ibrdss tgo bduntry hs bdnfhrloe my tgo survoyrospdneonts. Ugo prosonbo df tgo MhdSd`o bdlpoththvhty b`ustors bdnthnuos td onbduriko rokhdni` ehvorshty.

    Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos

    ;

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    9/35

    Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos Rdurbo1 Frinbo Mhdtobg Liy =392: 9?3 bdlpinhos

    Bdlpiny Rhzo ine Olp`dyoo Oeubithdn

    Nulmor df olp`dyoos @ovo` df Oeubithdn Ibghovoe my Olp`dyoos

    93

    9 td ?

    6 td 93

    99 td 23

    29 td 88

    Listors

    SgE

    Mibgo`drs Eokroo

    Ghkgsbgdd`

    933*

    =;/

    5/

    23/

    =5/

    96/

    2?/

    92/

    =5/

    =7/

    = 2

    Dur ini`yshs sgdws tgit bdlpinhos hn tgo @hfo Rbhonbos sobtdr rolihn, fdr tgo ldst pirt, sli`` strubturos

    tgit drhkhnito frdl ibieolhb rosoirbg ine olp`dy ghkg`y oeubitoe wdrjors. Eosphto tgo robont`y stdrlyobdndlhb onvhrdnlont hn Ourdpo, tgo hneustry eoldnstritoe hts vorsith`hty hn =39= my rovorshnk tgonokithvo trone df not bdlpiny broithdn, wgh`o tgo liadrhty df survoy rospdneonts '?7/( ropdrtoe ipdshthvo dut`ddj ine nd ehffhbu`thos pdsoe my strubturi` hssuos. Ibthvhthos hn tghs sobtdr iro lihn`y fdbusoedn eovo`dphnk tgoripouthb, ehikndsthb ine loehbi` eovhbo prdeubts hn tgo edlihn df gulin goi`tg, muthn robont yoirs B`ointobg bdlpinhos givo bdnthnuoe td krdw hn nulmor ine shzo. Ugo phpo`hno df tgoripouthb prdeubt eovo`dplont rolihns rdmust whtg i`ldst983 prdkrils hn tgo prddf df bdnbopt dr prob`hnhbi` pgiso df eovo`dplont ine 2= prdeubts hn tgo lhest df Sgiso HH trhi`s.

    Rhlh`ir td provhdus Sindrili stuehos, tgo liadrhty df bdlpinhos hn tghs yoirs pino` iro sli`` strubturos. ?;/

    df bdlpinhos givo 93 dr fowor olp`dyoos, wgh`o dn`y sovon bdlpinhos givo ldro tgin 933 olp`dyoos.]obruhtlont hn tghs hnndvithvo sobtdr hs lihn`y fdbusoe dn hnehvheui`s whtg ievinboe eokroos, is 62/ dfolp`dyoos gd`e ohtgor i Listors dr SgE `ovo` eokroo. 59?3 podp`o hn tdti` iro olp`dyoe hn tghs hnndvithvo sobtdr,lijhnk in ivoriko df== podp`o por bdlpiny.

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    10/35

    99

    Bdlpiny Iko, Drhkhn ine Edlihn df Ibthvhty

    Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos Rdurbo1 Frinbo Mhdtobg Liy =392: 979 bdlpinhos

    Drhkhn df tgo bdlpiny

    27/

    =8/ 22/93* yoirs

    6 td 93 yoirs

    3 td ? yoirs

    8/

    22/

    ?5/

    Ibieolhb ]osoirbg

    Rli`` Mushnoss Rtirtup

    Dtgor

    5/

    Rphndff frdlmhk bdlpiny

    Bdlpinhos my iko5 ?

    Edlihn df Ibthvhty

    Rdurbo1 Frinbo Mhdtobg, Liy =392: 976 bdlpinhos

    6

    Ugo liadrhty df Fronbg @hfo Rbhonbos bdlpinhos bdlo dut df tgo Ibieolhb sobtdr, fd` dwoe b`dso`y my sli``mushnoss ontropronours, wgh`o dn`y 5/ df tgo pino` drhkhnitoe is i sphndff frdl i mhk bdlpiny. Ughs yoirsrospdneonts prosont i goi`tgy ehstrhmuthdn hn torls df bdlpiny iko, sgdwhnk i rdukg`y ovon sp`ht motwoonstirtup stiko, krdwtg pgiso ine eovo`dpoe bdlpinhos. Ugo prdfh`o df tgo BODs hn dur survoy furtgor eoldnstritos tgo vhti`hty ine rosh`honbo df tgo ontropronourhi` sphrht hn tghs sobtdr1

    59/ df BODs givo moon tgo BOD df indtgor bdlpiny

    ;;/ df BODs iro fduneors df tgohr bdlpiny;5/ df BODs iro sbhonthsts my trihnhnk

    Gulin Goi`tg bdnthnuos td mo tgo ldst bdlldn edlihn df bdrpdrito ibthvhty ildnk tghs yoirs survoyrospdneonts. Inhli` Goi`tg ine Bdslothbs rolihn fdbus irois fdr liny bdlpinhos, wgh`o =39= siw inhnbroiso df ibthvhty hn tgo edlihn df Oquhplont & ]oikonts. @ddjhnk mrdie`y it B`ointobg ehsbhp`hnos, ibdlmhnoe 9=/ df ibthvhthos iro fdbusoe dn tgo Onvhrdnlonti`$Onorky, S`int Srdeubthdn ine Kroon Mhdtobgedlihns '93/ hn =399(.

    Gulin

    Goi`tg

    95/

    8/ 7/6/ ?/ ?/ 5/ 5/ 5/ 2/ 2/ 2/

    53

    3

    =3

    93

    2329/

    Inhl

    i`Goi`tg

    Oquhpl

    ont

    &]o

    ikonts

    Bdsl

    othbs

    Ikrh,fd

    deGul

    in

    Onvhr

    dnlont$On

    orky

    Loehbi

    `Eovhbo

    s

    ineOq

    uhpl

    ont

    Dtgo

    r

    Hnfdrl

    ithdn

    Uobgnd`dky

    S`intS

    rdeubthdn

    Ikrh,fd

    deInhli`

    Nindto

    bgnd`dky

    KroonMh

    dtobg

    /

    Ibthvhty

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    11/35

    9=

    Lorkors ine Ibquhshthdns=39= wis lirjoe my tgo inndunbolonts hn Eobolmor df twd liadr ibquhshthdns hn tgo Fronbg @hfo Rbhonbossobtdr. Ugo ehikndsthbs bdlpiny Oxdnght purbgisoe HnKon Mhdsbhonbos '98 L(, broithnk i now fu``y hntokritoe`oieor hn tgo fho`e df hnvhtrd ehikndsthbs my tgo nilo dfEhixdnght. Ughs wis fd``dwoe my tgo mhdpgirlibouthbi`bdlpinyVhvi`hs purbgiso df Iustrhin fhrl Hntorbo`` '922 L(, wghbg broitoe i now mhdtobg `oieor hn vibbhnosine inthmdehos my tgo nilo dfVi`novi RO. Dtgor L&I ibthvhty hnb`ueoe tgo purbgiso dfOb`it Sgirlibouthbi`smy F`ilo` Uobgnd`dkhos, tgo ibquhshthdn df mhdtobgnd`dky fhrl Srosthzhi my tgorindsthbs bdlpinyUgoriehikinetgo ibquhshthdn df ]&E fhrl Borop my Ourdfhns Ehsbdvory Rorvhbos.

    Bdlpiny Broithdns ine @hquheithdns

    5956

    =5

    5852

    ? 8

    =3=?

    95

    =337 =338 =393 =399 =39=

    Broithdns

    @hquheithdns

    =3

    53

    63

    3

    ,=3

    ,53

    Not

    Nulmor

    Xoir

    ;

    Iftor strukk`hnk td broito now bdlpinhos hn =399, tgo @hfo Rbhonbos sobtdr sgdwoe hts eynilhsl hn =39= mykonorithnk i not broithdn df2? bdlpinhos. Ughs trone bdhnbheos whtg dnkdhnk rdmust ibthvhty hn Lorkors ineIbquhshthdns ine bdnfhrls tgo funeilonti` stronktg df hnndvithdn hn tgo @hfo Rbhonbos hn Frinbo tdeiy.

    272=

    =6

    9

    2?

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

    Rdurbo1 Frinbo Mhdtobg Liy =392

    Nulmor df bdlpinhoshn Sindrili

    Olp`dyoos eob`iroe mySindrili rospdneonts

    HSDs

    =33;

    Ovd`uthdn df Joy Hneustrhi` Hnehbitdrs

    VB Funehnk 'L(

    Lirjotoe prdeubts

    Sum`hb Bdlpinhos

    932

    =337 =338 =393 =399 =39=

    923 9;3 =99 983 976

    2 65? ? 288 2 9;7 ? 26? 5 ==8 5 9?3

    ? 9 3 ; 6 7

    979 =32 939 972 9=9 927

    ; 92 99 =3 == =?

    9; =3 =9 =9 =7 26

    Xoir

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    12/35

    Oxport tosthldny

    go shtuithdn hs hlprd

    vhnk mut tgo sobtdr

    nooes td bdnthnuo

    td krdw, pirthbu`ir`y hn torls

    df pum`hb`y trieoe bdlpinhos.

    Ugoro iro tgroo bgi``onkos td

    ieeross1 hntornithdni`hzithdn,

    tgo spooe df tobgnd`dky trins

    for ine tgo ivih`imh`hty df fhninbhnk. Frinbo `ibjs oxports

    hn i`` tgroo irois ine nooes

    spobhi hsts tgit iro bipim`o df

    loisurhnk tgo truo vi`uo df

    in heoi ine ro`ithnk ht td tgo

    burront hneustry `inesbipo.

    [o nooe td `iunbg now prd

    aobts ldro quhbj`y wgh`o ro

    lihnhnk pithont fdr tgol td

    moir fruht.

    Fhninbhnk hs tgo joy. Hnsthtuthdni` hnvostdrs iro tdd ro`ubtint

    rhkgt ndw ine tgo vonturo bi

    phti`hsts ibthvo hn tgo @hfo

    Rbhonbos nulmor fir tdd fow.

    Hts hlpdrtint td givo @hfo

    Rbhonbos ontropronours, mut

    givhnk i stim`o df pirtnors td

    ibbdlpiny tgol tgrdukg oibg

    pgiso df fhninbhnk, frdl sooe

    td oxpinshdn, hs i`sd ossonthi`.

    Linikolont orrdrs iro is ox

    ponshvo is fhninbhi` rosdurbos

    iro riro: bdlpinhos nooe tdeovo`dp i `dnk torl vhshdn

    frdl tgo vory mokhnnhnk. Srd

    aobts run my i linikolont

    toil whtg eoop oxporthso hn

    ehvorso fho`es ine in imh`hty td

    sgrowe`y vi`uo tgohr hnto``ob

    tui` prdporty wh`` givo tgo

    most bginbo fdr subboss.

    Ldro tgin inytghnk tgo li

    nikolont toil nooes td mo

    im`o td broehm`y rospdne tdtghs quosthdn1 hn wgit wiy iro

    wo kdhnk td bginko pithonts

    `hvos4

    Sgh`hppo Sdu`otty

    Sgh`hppo Sdu`otty, LEBdFduneor, BOD ine Goie df @hfo

    Rbhonbos it Uruff`o Biphti`

    Gdndriry Srosheont df Frinbo Mhdtobg

    [o nooe td `iunbg now prdaobts ldro quhbj`y

    U92

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    13/35

    Ehstrhmuthdn df B`honts my Hneustry Robtdr

    Sgirlibouthb

    i`

    Hneustry

    98/

    95/

    8/7/

    6/?/

    5/ 5/ 5/ 5/2/

    =3

    =?

    3

    93

    ?

    9?

    ==/

    Mhdtobgn

    d`dky

    Sum`hb]o

    soirbg

    Goi`tg

    biro

    Fibh`hthos

    Bdsl

    othbHneustry

    Loehbi

    `Eovhbo

    s

    Ikrh,fd

    deHneustry

    Dtgo

    r

    Goi`tg

    biro

    Onvhr

    dnlonti`

    Bgol

    hbi`Hneustry

    Firlhnk$mr

    ooehnk

    95

    /

    8

    Ugo sdurbo df rovonuos fdr ldst bdlpinhos hn tghs yoirs Sindrili stuey hs shlh`ir td robont yoirs, whtg tgoSgirlibouthbi` ine Mhdtobgnd`dky hneustrhos, is wo`` is Sum`hb ]osoirbg @imdritdrhos, rolihnhnk tgo ldstfroquont bustdlors fdr Fronbg @hfo Rbhonbo bdlpinhos. Hn fibt, ;7/ df rospdneonts ropdrtoe it `oist dnoSgirlibouthbi` hneustry b`hont ine ?3/ ropdrtoe it `oist dno Sum`hb ]osoirbg @imdritdry b`hont.

    Sirtnorsghps ine stritokhb i``hinbos bdnthnuo td p`iy in hlpdrtint rd`o hn tgo Fronbg @hfo Rbhonbos hneustry. ?7/df tghs yoirs survoy rospdneonts ropdrtoe givhnk dno dr ldro pirtnorsghp hn p`ibo ine dvor533 tdti` pirtnorsghpsworo eob`iroe. Ugo fduneithdni` rd`o p`iyoe my tgo Fronbg ibieoly hn tgo @hfo Rbhonbos sobtdr sgdws up ikihnhn tghs edlihn, is noir`y gi`f '56/( df ropdrtoe pirtnorsghps woro bdnsthtutoe whtg ibieolhb rosoirbg hnsthtutos'hnb`uehnk BN]R, HNRO]L, Hnsthtut Sistour, Hnsthtut Burho ine ISGS(. Ugoso ro`ithdnsghps iro vory hntornithdni` hnnituro, is noir`y i tghre df pirtnors iro ndnFronbg drkinhzithdns. Furtgorldro, 9 dut df ovory ? Fronbg @hfoRbhonbos bdlpinhos whtg i pirtnorsghp gis eovo`dpoe in ibbdre whtg i k`dmi` Mhk Sgirli bdlpiny 'hnb`uehnkRindfh, K`ixdRlhtgJ`hno, Lorbj, Ndvirths, Ndvd Ndrehsj, Sfhzor, Rorvhor, UOVI, O`h @h``y ine Mrhstd`Lyors Rquhmm(,sgdwhnk tgit tgo bdnnobthdns whtg tgo pgirlibouthbi` hneustry rolihn quhto strdnk.

    Rdurbo1 Frinbo Mhdtobg Liy =392: 93; bdlpinhos

    )-"%/&+'

    (!*'

    ,.$3%9='

    25*'?&6./;-&'

    7/3/69&+'

    85*'

    1%+/9'

    (:*'

    Sirtnorsghps ine B`honts

    Ehstrhmuthdn df Sirtnorsghp Uypos

    Ibieolhb ]osoirbg

    Hneustry

    Mhdtobg

    Dtgor=6/

    93/

    97/

    56/

    7

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

    Rdurbo1 Frinbo Mhdtobg Liy =392: 9;6 bdlpinhos

    Hneustry

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    14/35

    Oxport tosthldny

    go bdnehthdns tgit

    rolihn untroitim`o

    iro tgo ldst ehffhbu`t

    td bdnquor, mut tgo ehvorshty

    df hntuhthvo heois ine ip

    prdibgos burront`y mohnkpursuoe stronktgons dur

    bginbos td lijo hlpibtfu`

    ievinbos. Is i liadr ibtdr

    hn tgo rosoirbg bdllunhty,

    Rindfh gis i strdnk hntorost

    hn p`ibhnk hts eovo`dplont

    toils hn in obdsystol df

    `hvo`y rosoirbg. Eosphto dur

    shzo, wo nooe pirtnors td

    bdnfrdnt dur vhowpdhnts inetd go`p robi`hmrito dur pors

    pobthvo ine rof`obthdns. Ht hs

    fdr tghs roisdn tgit wo iro hn

    bdnstint bdntibt whtg Mhdtobg

    ine Loetobg bdlpinhos,

    mdtg it tgo ontropronour ine

    hnvostdr `ovo`. Ughs hs pirthbu

    `ir`y truo hn Frinbo, wgoro gi`f

    df dur rosoirbg toils iro `d

    bitoe. Rindfh dffors hts hneus

    trhi` jndw`oeko ine k`dmi`

    lirjot ibboss hn pirtnorsghp

    shtuithdns, ine hn roturn wo

    robohvo in hlpdrtint bdlpdnont df broithvhty ine f`oxhmh`hty

    frdl @hfo Rbhonbos stirtup

    bdlpinhos.

    Hn i pirtnorsghp, wgit hs ldst

    hlpdrtint hs td brdss pitgs df

    ton ine td wdrj tdkotgor ine

    kot td jndw dno indtgor wo``

    frdl tgo vory mokhnnhnk. Ud

    roi``y muh`e sdlotghnk, ht hshlpdrtint td fhrst bdnfhrl tgit

    tgo pirtnors sgiro tgo silo

    uneorstinehnk df prdaobt

    dmaobthvos ine thlo`hno, wghbg

    i``dws tgo bd``imdritdrs td

    offobthvo`y monbglirj tgohr

    sbhonthfhb adurnoy tdkotgor.

    Sgh`hppo Kdupht

    Sgh`hppo KduphtVhbo Srosheont Bdrpdrito @hbonsos,

    Rtritoky & Mushnoss Eovo`dplont

    Rindfh

    Eosphto dur shzo, wo nooe pirtnors td bdnfrdnt

    dur vhowpdhnts

    U9?

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    15/35

    96

    Sitonts

    Sitonts Fh`oe

    Sitonts Oxp`dhtoe

    Frinbo$Ourdpo

    _RI

    ]ost df [dr`e

    9227

    ;88

    95;;

    93

    9=

    Sitonts Krintoe

    67?

    =65

    55?

    99

    ;5=

    =25

    =6;

    Ugo hnto``obtui` prdporty ibthvhthos df Fronbg @hfo Rbhonbo bdlpinhos bdnthnuo td mo vory hntornithdni` hn nituro,is 53/ df oxp`dhtoe pitonts woro krintoe ohtgor my tgo _nhtoe Rtitos Sitont Dffhbo dr i ndnOurdpoin pitontdffhbo 'Fhkuro 9=(. Ovon ldro to``hnk hs tgo fibt tgit62/ df pitont ipp`hbithdns woro fh`oe whtg i ndnOurdpoinpitont dffhbo 'Fhkuro 93(.

    Olp`dyhnk =5 podp`o ine givhnk moon hn mushnoss fdr i`ldst 93 yoirs, bdlpinhos oxp`dhthnk pitonts iro konori``ys`hkgt`y d`eor ine `irkor tgin tgo ivoriko fdr i`` survoy rospdneonts '== olp`dyoos ine 8 yoirs d`e(. Ughs yoirsrospdnsos rokirehnk pitont ibthvhty iro bdnshstont whtg ghstdrhbi` trones: Fronbg @hfo Rbhonbos bdlpinhos tonetd mrdieon tgohr hnto``obtui` prdporty kdi`s is tgoy eovo`dp ine dporito dvor i `dnkor porhde df thlo.

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

    Rdurbo1 Frinbo Mhdtobg Liy =392: 923 bdlpinhos

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    16/35

    Oxport tosthldny

    uh`ehnk i rdmust not

    wdrj df @hfo Rbhonbos

    bdlpinhos hs i prhd

    rhty fdr Frinbo. Ugo lobgi

    nhsls df suppdrt fdr tgo sob

    tdr iro hn p`ibo td eovo`dp tgo

    pdtonthi` vi`uo df heois kono

    ritoe my Fronbg rosoirbgorsine dur lhsshdn it mphfrinbo

    hs td prdvheo i typo df `ovor

    tgit wh`` offhbhont`y prdldto

    tgo hneustrhi` bgilphdns df

    tdldrrdw. Ehrobt ihe td hnnd

    vithdn hs wgit hs nooeoe fhrst

    df i``, tgrdukg sumshehos, bisg

    ievinbos ine hntorostfroo

    `dins. Ugon wo lust lihntihn

    tgo prdkril df tix suppdrtstgit hs hn p`ibo, spobhfhbi``y

    tgo ]osoirbg Uix Broeht 'BH](

    ine tgo Xdunk Hnndvithvo

    Ontorprhso 'AOH( eoshknithdn.

    Fhni``y, wo nooe td md`stor

    tgo oquhty hnvostlonts tgit

    ibbdlpiny ontropronours

    tgrdukg oibg stiko df tgohr

    prdaobt. Ugo Mhdtobg ine

    Loetobg toils it mphfrinbo

    liniko i bdlp`oto pdrtfd`hd

    df ehrobt ine hnehrobt fhnin

    bhnk voghb`os tgit suppdrt

    bdlpinhos it ovory stop df

    tgohr eovo`dplont, frdl sooe

    stiko td liturhty. Dur toils

    ine oxports iro prosont i``

    dvor tgo bduntry wdrjhnk td

    kuheo ontropronours hn tgohroffdrts td put i strubturo

    irdune tgohr hnndvithdns.

    Dnbo wo givo lieo in hn

    vostlont, i fhninbhi` ievhsdr

    ine i sumaobt littor oxport

    frdl mphfrinbo adhn tgo mdire

    df ehrobtdrs df tgo bdlpiny

    ine mokhn wdrjhnk td eovo`dp

    `dnktorl vi`uo. Ovon hf tdeiy

    mphfrinbo hs hnvostoe hn dn`y97 Sothtos ot Ldyonnos On

    troprhsos, wo rolihn itton

    thvo td tgo rhsj df eostimh`hzhnk

    tgo prhvito hnvostdr lirjot.

    @hjo dur poors hn tgo prhvito

    sobtdr, wgd iro i`sd dfton dur

    pirtnors, wo fivdr prdaobts

    whtg strdnk hneustrhi` ro`o

    vinbo ine prdfosshdni` li

    nikolont toils.

    Li`ys Forroro

    Li`ys ForroroEhrobtdr df Hnvostlonts

    Fdnes Rtritkhquo eHnvosthssolont

    mphfrinbo

    Dur oxports iro prosont i`` dvor tgo bduntrywdrjhnk td kuheo ontropronours

    M9;

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    17/35

    97

    Ugoripouthb Srdeubts my Fdbus Iroi

    Dnbd`dky

    9;/

    8/ 7/

    5/ 5/ 5/

    =8/

    Hnfo

    bthdus

    ehsoisos

    Bontri`

    Norvd

    us

    Rystol

    L

    otimd`hsl

    Bire

    hdvi

    sbu`ir

    eovhb

    os

    Eorl

    itd`dky

    Sirishthb

    eosoisos

    6/

    Dtgo

    r

    2/

    Konothb

    eosoisos

    =/

    Dptgi`l

    d`dky

    =/

    ]gul

    itd`dky

    =/

    Hlluno

    Rysto

    l3

    =3

    93

    23

    /

    FdbusIroi

    =/

    Hnf`illithdn

    92

    Rdurbo1 Frinbo Mhdtobg Liy =392: 8? bdlpinhos

    Rdurbo1 Frinbo Mhdtobg Liy =392, eiti ndrli`hzoe td 933 bdlpinhos por yoir

    Ugoripouthb Srdeubts my Rtiko df Eovo`dplont

    78

    ?3

    =3

    53

    63

    73

    933

    3Srob`hnhbi` Sgiso 9 Sgiso = Sgiso 2 ]okhstrithdn Bdllorbhi`hzithdn

    95

    =337 =338 =393 =399 =39=

    62

    ???;

    =2=6

    53=8

    2529

    =9=;

    2?25

    996 7 6 7 7 2 5 2 5

    93;

    9=

    =3=6

    Nulmor df Srdeubts

    Rtiko dfEovo`dplont

    Ugo phpo`hno df tgoripouthb @hfo Rbhonbos prdeubts uneor eovo`dplont rolihns rdmust hn Frinbo. Is hn yoirs pist,tgo edlhnint tgoripouthb iroi df fdbus rolihns Dnbd`dky '=8/(. Ughs yoir siw in hnbroiso hn prdeubts ieerosshnkHnfobthdus Ehsoisos '9;/ vs 7/ hn =399(, tgo Bontri` Norvdus Rystol '8/ vs ;/ hn =399( ine Lotimd`hsl'7/ vs 6/ hn =399(. Dn ivoriko, tgo 8? bdlpinhos eovo`dphnk tgoripouthb prdeubts iro 8 yoirs d`e, givo =?olp`dyoos, lihntihn 2 pirtnorsghps, spone 2.5L i yoir dn ]&E ine oxp`dht 95 pitonts.

    =78 tdti` prdeubts woro eob`iroe tghs yoir, rinkhnk frdl tgo prddf df bdnbopt stiko td bdllorbhi`hzithdn, ine?9/ '8? df tgo 976( df bdlpinhos tgit rospdneoe td tgo survoy ropdrtoe givhnk i tgoripouthb prdeubt uneoreovo`dplont. Ugo oir`y, hnndvithvo stikos df prdeubt eovo`dplont rolihn eynilhb hn tghs yoirs bdgdrt, wgoro65/ df prdeubts woro ropdrtoe td mo hn tgo Srddf df Bdnbopt dr Srob`hnhbi` ]osoirbg stikos. =?/ df prdeubtsiro hn Sgiso H, HH dr HHH b`hnhbi` trhi`s ine, porgips ldst hlprosshvo`y, =? prdeubts iro it tgo bdllorbhi`hzithdnstiko, bdlpiroe whtg == hn =399.

    F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX

    Srdeubts

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    18/35

    98

    Ehikndsthb Srdeubts my Fdbus Iroi

    Dnbd`dky

    96/9?/

    9=/

    5/ 5/2/

    98/

    Hnfo

    bthdus

    ehsoisos

    Bontri`N

    orvd

    us

    Rystol

    Lotimd`hsl

    Ikrh,fd

    de

    ]osoirbg

    Rd`uthd

    ns

    Gdsphti`

    Rd`uthd

    ns

    7/

    Dtgo

    r

    2/ 2/ 2/ 2/

    Ehkosthvo

    eovhb

    os

    Hlluno

    Rystol

    ]osphri

    tdry

    eovhb

    os

    Golitd`dky

    =3

    3

    93

    ?

    9?

    FdbusIroi

    /

    9?

    Dtgor Srdeubts;3 bdlpinhos ropdrtoe givhnk dtgor, ndntgoripouthb prdeubts uneor eovo`dplont, subg is hn vhtrd dr hn vhvdehikndsthbs, loehbi` eovhbos ine dtgor ievinboe tobgnd`dkhos. Dn ivoriko tgoso bdlpinhos iro 8 yoirs d`e,givo =9 olp`dyoos, lihntihn 2 pirtnorsghps, hnvost 9.?L hn ]&E innui``y ine oxp`dht 6 pitonts. I tdti` df78 Ehikndsthb prdeubts iro mohnk eovo`dpoe my 53 ehfforont @hfo Rbhonbos bdlpinhos. 98/ df tgoso Ehikndsthbs iro tirkothnk Dnbd`dky, wgh`o 96/ fdbus dn tgo Bontri` Norvdus Rystol ine 9?/ ieeross tgo HllunoRystol. Loehbi` Eovhbos bdlpinhos bdnthnuo td prdvheo in hlprosshvo stim`o df hnndvithvo prdeubts. Ughs

    yoir siw 8 bdlpinhos ropdrt i tdti` df 98 loehbi` eovhbos uneor eovo`dplont, whtg ldst prdeubts fdbushnkdn Dnbd`dky '=6/(, Drtgdpoehbs '=9/( ine Birehdvisbu`ir '96/(.

    Frinbo Mhdtobg

    HSRON

    Rindfh

    ] & E Hnvostlont " df Sgiso 9 " df Sgiso = " df Sgiso 2

    =?= L

    2=3 L

    6,277 L

    98 =5 6

    9

    ?5

    7

    ?5

    ?

    =9

    Bdlpirhnk tgo ]&E hnvostlonts lieo my twd Fronbg Sgirlibouthbi` bdlpinhos whtg tgdso df ?8 Mhdtobgnd`dky bdlpinhos frdl tgo Sindrili survoy eoldnstritos tgo offhbhonby df tgo @hfo Rbhonbos sobtdr hn Frinbo.[htg `oss ]osoirbg ine Eovo`dplont sponehnk, tgoso eynilhb @hfo Rbhonbos bdlpinhos hn Frinbo iro im`otd mrhnk ldro prdeubts hntd tgo b`hnhbi` trhi` pgiso tgin tgohr Sgirlibouthbi` hneustry poors. Ugo ehspirhthossoon hn tghs bgirt go`p oxp`ihn tgo strdnk robont krdwtg hn tgo nulmor df now`y ipprdvoe loehbithdns tgitdrhkhnito frdl tgo edlihn df mhdtobgnd`dky.

    Bdlpirhsdn whtg Fronbg Sgirlibouthbi` Bdlpinhos

    Rdurbo1 Frinbo Mhdtobg Liy =392: 53 bdlpinhos

    Rdurbo1 Frinbo Mhdtobg Liy =392: ?8 bdlpinhos: MhdBontury

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    19/35

    =3

    K`dmi` Sorspobthvo df Robtdr Funehnk

    Ovd`uthdn df @hfo Rbhonbos Hneustry Funehnk 'L(

    939 9=9927

    =32

    9=

    968

    =337 =338 =393 =399 =39=

    Vonturo Biphti`

    HSD

    933

    =33

    233

    533

    ?33

    3

    Robdneiry Sum`hb Dfforhnks

    972

    972

    936

    8=

    ;5

    956

    73

    937

    =392 XUE

    2?29

    L

    Xoir

    96

    Ugo tdti` hnvostlont lieo hn tgo Fronbg @hfo Rbhonbos sobtdr hn =39= rdso my =;/ td 265 L. Krdwtg wiserhvon my strdnk eoline frdl tgo pum`hb lirjots '*?8/(, is tgo hneustry ropdrtoe ohkgt subbossfu` HSDs. VonturoBiphti` funehnk '*95/( ine Robdneiry Sum`hb Dfforhnks '*7/( siw onbdurikhnk yoirdnyoir hnbroisos is wo``.

    Rdurbo1 Frinbo Mhdtobg Liy =392

    Hn robont yoirs, fhninbhi` suppdrt fdr tgo @hfo Rbhonbos sobtdr hn Frinbo gis drhkhnitoe prhlirh`y frdl

    pum`hb sdurbos, mo tgoy pum`hb stdbj lirjots dr kdvornlont prdkrils. HSD ibthvhty my @hfo Rbhonbosbdlpinhos roibgoe hts ghkgost `ovo` ovor hn =39=, whtg robdres mohnk mrdjon mdtg hn torls df tgo nulmordf HSDs bdlp`otoe ine tgo tdti` ildunt rihsoe. Ontropronours i`sd bdnthnuo td eopone goivh`y dn tgoliny kdvornlont prdkrils tgit suppdrt ydunk, hnndvithvo bdlpinhos whtg ibthvhthos fdbusoe dn]osoirbg ine Eovo`dplont hn ievinboe sbhonthfhb fho`es.

    F]INBO1 FHNINBHNK HNNDVIUHDN

    =39= =392 Bginko

    HSD

    VB

    RSD

    993 29 ;=/

    5?

    =;

    937

    2?

    953/

    23/Udti` 97= 9;5 5/

    Funehnk Bdlpirhsdn1 Ainuiry td Liy 'L(

    Rdurbo1 Frinbo Mhdtobg Liy =392

    Xoir

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    20/35

    =9

    _so df Sum`hb Lirjots

    58

    9= 32;

    =33? =336 =33; =337 =338

    Ildunt ]ihsoe " df HSDs

    53

    73

    9=3

    963

    3

    92?936

    =393

    8=

    =399

    956

    =39=

    29

    =

    5

    6

    7

    93

    3 Xoir

    Nulmordf HSDs

    Ildunt]ihsoe 'L(

    =

    2

    ?

    9

    ;

    6

    7

    2

    I tdti` df956 L wis rihsoe frdl tgo pum`hb lirjots hn =39=, i strdnk hnbroiso mdtg hn vi`uo '*?8/( ine

    hn nulmor '*22/( bdlpiroe whtg =399. Ugo `irkost dporithdns woro bdlp`otoe my EMV Uobgnd`dkhos'59 L(, ODR Hlikhnk '27 L( ine Iedbhi '=; L(. Is hn =399, tgoro wis i proedlhninbo df LoeUobgbdlpinhos ildnk tgdso fh`hnk fdr HSDs hn =39= '6 df 7 hn =39= vs. ? df 6 hn =399(. Ugo ro`hinbo dn pum`hbhnvostdrs bdnthnuos td mo i joy rosdurbo fdr tgo @hfo Rbhonbos sobtdr, is tgroo bdlpinhos givo i`roiey bdneubtoe HSDs hn =392, rihshnk i bdlmhnoe 29 L.

    =392 XUE

    Ovd`uthdn df Fronbg @hfo Rbhonbos HSDs dn NXRO Ourdnoxt 9;

    Rdurbo1 Frinbo Mhdtobg Liy =392

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    21/35

    Oxport tosthldny

    gh`o tgo pd`hbhos

    df goi`tg biro

    rohlmursolont

    rolihn tgo prordkithvo df

    oibg lolmor stito, tgo Ou

    rdpoin @hfo Rbhonbos sobtdr

    gis mobdlo i roi`hty hn austton yoirs. Ontropronourhi`

    toils iro ldro oxporhonboe

    ine hntornithdni` tdeiy ine

    tgoy dfton bdlmhno i lhx df

    sbhonthfhb ti`ont frdl liny ehf

    foront bduntrhos. It tgo silo

    thlo, hnvostdr krdups nd `dn

    kor fdbus tgohr hnvostlonts

    oxb`ushvo`y dn dno bduntry

    ine givhnk i dbi` hnvostdr ittgo tim`o gis mobdlo `oss df

    i nobosshty. Ughs Ourdpoin

    bdnvorkonbo hs soon hn pum`hb

    fhsbi` pd`hby is wo``, whtg

    oxilp`os `hjo tgo ]osoirbg

    Uix Broeht pissoe my tgo

    Fronbg kdvornlont hnsphrhnk

    dtgors hn Ourdpo td onibt sh

    lh`ir loisuros, ndtim`y tgo

    _nhtoe Jhnkedl ine Kor

    liny. Ugo sgirhnk df bdlpo

    tonbhos ildnk Ourdpoin ro

    ku`itdry ikonbhos gis fhni``y

    subbooeoe hn prdvhehnk i

    trinsnithdni` porspobthvo ine

    wo iro mokhnnhnk td soo i Ourdpoin spobhi`ty hn bortihn ed

    lihns df rosoirbg, subg is

    Loehbi` Eovhbos.

    Ugo hneustry hs Ourdpoin mut

    sd hs tgo brhshs ) Xdu givo td

    fhkgt td soo ydur prdaobt krdw,

    ine tgit hs truo ovorywgoro

    hn Ourdpo. Ndnotgo`oss, tgo

    sobrot fdr subboss hs truo ovorywgoro1 ontropronours nooe

    td mo ilmhthdus ine bdnfheont

    ine tgoy nooe td fhne hnvos

    tdrs tgit sgiro tgohr vhshdn. Ui

    jhnk tgo thlo td eobheo gdw

    td broito ine sgiro tgo vi`uo

    df in heoi hs vhti``y hlpdrtint.

    ]ifi`o Udrealin

    ]ifi`o Udrealin, LELinikhnk Sirtnor

    Rdfhnndvi Sirtnors

    Ugo sgirhnk df bdlpotonbhos ildnk Ourdpoin

    roku`itdry ikonbhos gis fhni``y subbooeoe

    [==

    F]INBO1 FHNINBHNK HNNDVIUHDN

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    22/35

    Dtgor fdrls df fhninbhnkRooe fhninbhnk rolihns i brubhi` bdlpdnont td tgo oir`y stikos df tgo mushnoss eovo`dplont byb`o hn tgo@hfo Rbhonbos sobtdr. Rooe funehnk my Fronbg Mushnoss Inko`s wis stim`o hn =39= hn bdlpirhsdn whtg =399,ildunthnk td aust dvor? L eurhnk mdtg yoirs.

    I`sd hn =39=, Fronbg @hfo Rbhonbos bdlpinhos woro ildnk tgo oir`y iedptors df brdwefunehnk, i now, hntor

    notbdllunhtymisoe funerihshnk bdnbopt tgit gis mobdlo dno df tgo gdttost trones fdr fhninbhnk hnndvithdnirdune tgo wdr`e. Hn Dbtdmor, Udu`dusomisoe mhdtobg bdlpinyINUIMHD robdreoe wgit gis moon eosbrhmoeis tgo fhrst brdwefunehnk dporithdn ovor bdlp`otoe my i mhdtobg bdlpiny.

    Vonturo Biphti`

    Ehstrhmuthdn df VB Funehnk 'L(

    57

    992

    6;

    =393 =399 =39=

    53

    73

    9=3

    963

    =33

    3

    73

    ?=

    ?3

    6

    6

    Mhdtobg

    B`ointobg

    Loetobg

    " df eoi`s

    =?

    Ildunt ]ihsoe 'L(

    Xoir

    27

    59

    93

    =3

    23

    53

    ?3

    Nulmor df Dporithdns

    3

    97

    Hnvostlonts my vonturo biphti` funes hnbroisoe hn =39= td 927 L, ikihnst9=9 L hn =399. I tdti` df 59eoi`s woro dmsorvoe, bdlpiroe whtg 27 hn =399, wgh`o tgo ivoriko ildunt hnvostoe por eoi` krow frdl2,= L hn =399 td 2,? L hn =39=. I``dbithdn df hnvostlonts my funehnk rdune wis wo`` ehstrhmutoe, whtgRorhos M fhninbhnks oiehnk tgo wiy it58 L, fd``dwoe my Rorhos B fhninbhnks df25 L, Rorhos I fhninbhnksdf=6 L ine Rorhos E fhninbhnks df93 L. Ughs ehstrhmuthdn bdlpiros fivdrim`y whtg =399, wgon dvor?5/ df VB ourds woro i``dttoe eurhnk Rorhos B rdunes.

    Hnvostlonts hn Mhdtobgnd`dky bdlpinhos `oe tgo oxpinshdn hn funehnk '*67/( ine go`poe bdlponsito fdri erdp hn Loetobg eoi`s '=2/(. Uwd `irko rdunes hn =39= hnb`ueoe i 92 L Rorhos M fhninbhnk my Sdxo``R.I. ine i 9=,5 L Rorhos B fhninbhnk my UxBo`` R.I. I vory strdnk stirt td =392 gis moon uneorwiy is wo``,whtg i 2= L Rorhos I fhninbhnk my KonRhkgt Mhd`dkhbs ine i =7 L Rorhos E fhninbhnk my Ruporsdnhb Hlikhno mdtg mohnk inndunboe hn Iprh`.

    Bdrpdrito VonturoBdrpdrito Vonturo hnvostlonts lieo my Sgirlibouthbi` bdlpinhos p`iy in hlpdrtint rd`o hn suppdrthnk tghshnndvithvo sobtdr. Lrhoux Eovo`dplont bdnthnuoe td suppdrt tgo eovo`dplont df @ydnmisoe loetobg bdlpiny Mhdlup ine Rtrismdurkmisoe ehikndsthbs fhrl MhdFh`l Bdntrd`, wgh`o Ndvirths Vonturo tddj pirt hn

    tgo Rorhos I rdune df dpgtgi`lhb tgoripouthbs bdlpiny Konshkgt Mhd`dkhbs ine Mdogrhnkor Hnko`gohlVonturo Fune robont`y inndunboe p`ins td hnvost hn dbu`ir tgoripouthbs fhrl Oyovonsys.

    Rdurbo1 Frinbo Mhdtobg Liy =392

    =2

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    23/35

    =5

    BH]

    Ugo rosoirbg tix broeht 'BH]( hs i tix roeubthdn eoshknoe td onbduriko tgo ]&E ibthvhthos df Fronbg bdlpinhos.79 bdlpinhos hn tghs yoirs stuey ropdrtoe tijhnk ievintiko df tgo rosoirbg tix broeht fdr i tdti` monofht dfi`ldst67 L. ?=/ df bdlpinhos eriwhnk dn tgo rosoirbg tix broeht givo 9 td 93 olp`dyoos ine 67/ givomoon hn dporithdn fdr oss tgin 93 yoirs, sgdwhnk tgit tghs hlpdrtint prdkril bdnthnuos td monofht sli``, ydunkine hnndvithvo bdlpinhos. Ugoso 79 bdlpinhos robohvhnk tgo rosoirbg tix broeht tdkotgor ibbdunt fdr 98 prdeubtshn Sgiso HH b`hnhbi` trhi`s, 6 prdeubts hn Sgiso HHH b`hnhbi` trhi`s ine 96 prdeubts ontorhnk bdllorbhi`hzithdn.

    9=

    9;

    =336 =33; =337 =338 =393

    5

    7

    96

    =3

    3

    =399

    " df now bdlpinhoseob`irhnk AOH stitus

    Xoir

    =39=

    9=99 99

    8

    =

    Rdurbo1 Frinbo Mhdtobg Liy =392

    F]INBO1 FHNINBHNK HNNDVIUHDN

    98

    Kdvornlont Ruppdrt

    Krints ine ]osoirbg RumshehosIldnk tgo 976 rospdneonts td tghs yoirs survoy, 927 ropdrtoe robohvhnk i krint dr sumshey td suppdrt tgohribthvhty hn =39=. Ughs fhninbhi` isshstinbo wis ehstrhmutoe is fd``dws1

    `?= bdlpinhos robohvoe in hnvostlont sumshey:

    `65 bdlpinhos robohvoe dporithnk sumshehos, tdti`hnk 53,? L:

    ` 75 bdlpinhos robohvoe i ropiyim`o `din, tdti`hnk ;2 L:

    ` 28 bdlpinhos robohvoe suppdrt frdl DROD, tdti hnk 69 L:

    ` =2 bdlpinhos robohvoe suppdrt frdl tgo Ikonbo Nithdni`o eo ]obgorbgo 'IN](, tdti`hnk ?.? L:

    ` =2 bdlpinhos robohvoe suppdrt frdl i Ourdpoin prdkril, tdti`hnk 7,2 L.

    Xdunk Hnndvithvo Ontorprhso Rtitus 'AOH(

    AOHUgo Xdunk Hnndvithvo Bdlpiny 'AOH( stitus, eovo`dpoe my tgo Rtritokhb Bdunbh` fdr Hnndvithdn ine suppdrtoemy Frinbo Mhdtobg hn =335, prdvheos i nulmor df tix ine sdbhi` soburhty oxolpthdns fdr SLOs tgit i``dbito it`oist9?/ df tgohr tdti` bdsts td rosoirbg ine eovo`dplont. 963 bdlpinhos olp`dyhnk 873 tdti` wdrjors hn tgo

    ]osoirbg ine Eovo`dplont hn Mhdtobgnd`dky sobtdr monofhtoe frdl tgo AOH stitus hn =393, ibbdrehnk td tgo=39= EKBHR ropdrt vi`uithdn eu ehspdshthf AOH. ?3/ df bdlpinhos hn tghs yoirs stuey ropdrtoe givhnk dptoefdr tgo AOH stitus. Furtgorldro, i`` 92 df tgo bdlpinhos hn tghs yoirs bdgdrt tgit woro broitoe hn =399 dr =39=eob`iroe givhnk ipp`hoe fdr tgo stitus. Ugo AOH stitus rolihns i brubhi` suppdrt fdr ontropronours hn tgo @hfoRbhonbos sobtdr.

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    24/35

    Oxport tosthldny

    neustrhos df tgo futuro

    `hjo Mhdtobgnd`dky ine

    Loehbi` ]osoirbg, is

    wo`` is ]onowim`o Onorky

    ine GhkgUobg, wh`` mo tgo

    prhdrhty df mphfrinbo, wgh`o Lh

    brdontorprhsos 'USO(, Rli``

    ine Loehul Ontorprhsos'SLO( ine Hntorloehito Rhzo

    Ontorprhsos 'OUH( wh`` mo tgo

    tirkot strubturo df tgo bdl

    pinhos tgit wo wh`` sooj td

    suppdrt. @hfo Rbhonbos hs dno

    df tgroo liadr stritokhb sob

    tdrs df fdbus tgit gis ghstdrh

    bi``y soon strdnk suppdrt

    frdl tgo drkinhzithdns tgit

    lijo up mphfrinbo. Ugo hntokrithdn df FRH, DROD ine BEB

    Ontorprhsos i``dws mphfrinbo

    td dffor bdlpinhos i wheo eh

    vorshty df fhninbhi` suppdrt dp

    thdns ine khvos us tgo bipi

    mh`hty td hntorvono dn mdtg tgo

    bisg ine oquhty pdshthdns df

    bdlpinhos td suppdrt tgohr

    eovo`dplont.

    Ugo strubturo df tgo fhninbhnk

    bgihn hs i bdnstint bdnborn

    df tgo Fune df Funes toil.mphfrinbo wh`` bdntrhmuto td

    tgo iunbg df now hnvostlont

    toils, prdvheoe tgoy iro ox

    porhonboe, broehm`o ine iro

    fdbusoe dn sumaobts tgit iro

    hnieoquito`y dr ndt it i`` bd

    voroe my tgo burront lirjot.

    Hneooe wo iro p`innhnk td

    pirthbhpito hn funerihshnks fdr

    sovori` now @hfo Rbhonbosfunes tghs yoir, is tgroo eds

    shors iro uneor b`dso oxilh

    nithdn it tgo ldlont.

    Siu`Frindhs Fdurnhor

    Siu`Frindhs FdurnhorOVS Hnndvithdn Ehvhshdn

    mphfrinbo

    @hfo Rbhonbos hs dno df tgroo liadr stritokhb

    sobtdrs df fdbus

    H=?

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    25/35

    =6

    Mrizh`

    Biniei

    _RI

    Korliny

    Hti`yRpihn

    Rwoeon

    _nhtoeJhnkedl

    Fhn`ine

    Sd`ine

    Sdrtuki`

    Rwhtzor`ine

    Notgor`ines

    Mo`khul

    Frinbo Iustrhi

    Eonlirj

    ]dlinhi

    9 =

    =7 27

    9

    9 = 2

    9

    6 8

    9 8

    9

    9

    =

    9 5

    =

    = 6

    9 ?

    2 2

    ? 95

    HNUO]NIUHDNI@ SO]RSOBUHVOR

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    26/35

    =;

    Iustri`hi

    BghniAipin

    Rhnkipdro

    Uiwin

    Hsrio`

    Now Qoi`ine

    Frinbo

    2

    ? =Rdutg Jdroi

    9

    = ;

    9 9

    =

    9

    9

    Nulmor dfFronbg bdlpinhos

    hlp`intoe

    Nulmor dfpirtnorsghps my

    Fronbg bdlpinhos

    Rdurbo1 Frinbo Mhdtobg Liy =392

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    27/35

    =7

    @hfo Rbhonbos Bdlpinhos dn tgo NXRO Ourdnoxt$I`tornoxt

    ==

    929

    =33; =337 =338 =393 =399

    Mo`khulFrinbo

    ?3

    933

    9?3

    =33

    =?3

    3

    233

    Notgor`ines

    87 936 8=

    =39=

    92?

    ?6

    9=

    956

    Xoir

    =3

    @hfo Rbhonbos HSDs hn OurdpoHn robont yoirs Frinbo gis eriwn dn tgo rosdurbos df tgo pum`hb lirjots ldro ibthvo`y tgin dtgor @hfo Rbhonbossobtdrs hn Ourdpo. Frdl =33; tgrdukg =39=, tgoro woro =; subbossfu` HSDs dn tgo NXRO Ourdnoxt dr I`tornoxtoxbginko bdneubtoe my Fronbg @hfo Rbhonbos bdlpinhos tgit rihsoe i tdti` df589 L. Dvor tgo silo thloporhde, tgoro woro shx HSDs my Mrhthsg @hfo Rbhonbos bdlpinhos dn tgo @dnedn Rtdbj Oxbginko tgit rihsoe i tdti`df27 L, tgroo HSDs my Rwhss @hfo Rbhonbos bdlpinhos dn tgo RHW Rwhss oxbginko tgit rihsoe BGF 92; L inetwd HSDs my Korlin @hfo Rbhonbos bdlpinhos dn tgo Eoutsbgo Mrso tgit rihsoe 57 L.

    2 9?=L

    ? 9;8L

    2;L

    Frinbo

    Mo`khul

    Notgor`ines

    Lirjot Biphti`hzithdns my Bduntry1 NXRO Ourdnoxt ine I`tornoxtMhdtobgnd`dky ine Loehbi` Oquhplont Bdlpinhos 'L(

    =6 df tgo 2; Ourdpoin bdlpinhos trieoe dn tgo NXRO Ourdnoxt ine I`tornoxt oxbginkos whtg tgo hneustryb`isshfhbithdn df Mhdtobgnd`dky dr Loehbi` Oquhplont iro df Fronbg nithdni`hty, wgh`o Fronbg bdlpinhos bdnsthtuto6=/ df tgoso bdlpinhos tdti` lirjot biphti`hzithdn.

    @hfo Rbhonbos HSD Funerihshnk my Bduntry1

    NXRO Ourdnoxt ine I`tornoxt

    '9(

    '=(

    '?(

    '9(

    '9(

    '9( ';('6(

    '7(

    Rdurbo1 Frinbo Mhdtobg Liy =392:

    'n( < nulmor df HSDs

    Ildunt]ihsoe 'L(

    Rdurbo1 Mdursdrili, 9? Liy =392

    HNUO]NIUHDNI@ SO]RSOBUHVOR

    =9

    2?3

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    28/35

    NXRO NOWU Mhdtobg Hneox

    =8

    Ibbdrehnk td i Ainuiry =2, =392 NXRO Ourdnoxt pross ro`oiso, tgo mhdtobgnd`dky sobtdr wis dno df tgo tdpporfdrlhnk sobtdrs hn =39= whtg tgo SinOurdpoin Noxt Mhdtobg Hneox kihnhnk6;.58/. It tgo sukkosthdn dfFrinbo Mhdtobg, tgo Noxt Mhdtobg Hneox wis broitoe hn =337 td go`p eriw ittonthdn td tghs hnndvithvo sobtdrhn Ourdpo. Ugo Noxt Mhdtobg Hneox hs bdlpdsoe df bdlpinhos `hstoe dn ohtgor tgo Ourdnoxt dr I`tornoxtlirjots tgit givo in HBM b`isshfhbithdn df 5?;2 'Mhdtobgnd`dky(: 96 df tgo =2 bdlpinhos tgit bdnsthtutotghs hneox iro Fronbg.

    NOWU Mhdtobg Hneox

    ;6=,29

    23 ebolmro

    =399

    29 ebolmro

    =39=

    9 =;6,79

    Rdurbo1 NXRO Ourdnoxt Liy =392:

    ==

    Fdbus dn Fronbg pum`hb`y qudtoe bdlpinhos hn @hfo Rbhonbos

    Hn =39=, tgoro woro 26 Fronbg @hfo Rbhonbos bdlpinhos `hstoe dn pum`hb stdbj oxbginkos. Ldst iro `hstoe hn Sirhs dn ohtgor tgo NXRO Ourdnoxt dr I`tornoxt oxbginkos,wgh`o dno bdlpiny, F`ilo` Uobgnd`dkhos, hs `hstoe dn tgo _R NIREIY. Hn =39=, tgoso26 pum`hb`y`hstoe bdlpinhos bdlmhnoe td olp`dy 2 662 olp`dyoos, hnvost23= Lhn ]&E ine konorito ?72 L hn rovonuos '*8/ frdl =399(. Ugo bd``obthvo lirjotbiphti`hzithdn df tgoso bdlpinhos dn Liy 9?, =392 wis noir`y 5,9 M.

    Voxhl, i LoeUobg bdlpiny misoe noir Udu`duso wdrjhnk dn troitlonts fdr triulithbsphni` pitgd`dkhos, wdn tgo =39= NXRO I`tornoxt Srhzo fdr tgo subboss df hts HSD hn Iprh`ine fdr tgo strdnk porfdrlinbo df tgo stdbj tgit onsuoe.Birlit, in H`oeoFrinbo iroibdlpiny tgit robont`y kihnoe ipprdvi` td bdneubt gulin b`hnhbi` trhi`s df hts irthfhbhi`goirt, bdnthnuos td gd`e tgo ghkgost lirjot biphti`hzithdn 'dvor?=? L dn Liy =9,=392( ildnk tgo ldro tgin =33 tdti` bdlpinhos `hstoe dn tgo NXRO I`tornoxt stdbjoxbginko. Mdtg df tgoso bdlpinhos woro fhninboe my Uruff`o Biphti`, wghbg wis tgoldst ibthvo vonturo fune suppdrthnk Fronbg SLOs hn =39= ibbdrehnk td tgo -HnehbitourBgiussdn Fhninbo.-

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    29/35

    Oxport tosthldny

    htg dvor 23 pum`h

    b`y qudtoe @hfo

    Rbhonbos bdlpi

    nhos, ht hs b`oir tgit i `okhthlito

    notwdrj df lituro Mhdtobg ine

    Loetobg bdlpinhos oxhsts td

    eiy hn Frinbo. Ugo sobtdr gisprdkrossoe riphe`y hn Frinbo

    dvor tgo ist 5 dr ? yoirs, wgh`o

    krdwtg hn ldst dtgor Ourdpoin

    bduntrhos gis ovo`oe dff. Rup

    pdrt frdl fhsbi` pd`hby 'BH]( gis

    moon i strdnk erhvor, mut sd

    gis tgo ghkg qui`hty df sbhonth

    fhb oeubithdn hn tghs bduntry.

    K`dmi``y spoijhnk, Frinbo hs

    gd`ehnk pibo hn tgo hnndvithdnribo ine lihntihns i roi` pd

    tonthi` fdr eovo`dphnk ehsrup

    thvo tobgnd`dkhos hn i virhoty

    df fho`es, subg is loehbi` hli

    kory, sphni` tgoripouthbs ine

    hllundtgoripy.

    Ugo bdntrist whtg tgo _nhtoe

    Rtitos rolihns shknhfhbint hn

    rokire td dno ossonthi` pdhnt1

    brhthbi` liss. Sum`hb`y trieoe

    Fronbg @hfo Rbhonbos bdlpi

    nhos typhbi``y olp`dy 9? td 23

    ldst`y ]&E wdrjors ine iro

    fdbusoe prhlirh`y dn tgo eovo

    `dplont df dno f`iksghp prd

    eubt td mo prdldtoe my wiy df

    i pirtnorsghp whtg i `irkor hn

    eustrhi` bdlpiny. Ughs ldeo`

    gis lieo ht sdlowgit unroi`hsthb fdr i bdlpiny td rolihn

    hneoponeont wgh`o krdwhnk td

    tgo shzo df in hneustry `oieor

    ine tgo unfivdrim`o obdndlhb

    ine roku`itdry onvhrdnlonts

    givo bdlpduneoe tgo bgi`

    `onko. Ud ittihn brhthbi` liss,

    i stritoky df oxtorni` krdwtg

    nooes td tijo dvor ine ibbo

    `orito tgo eovo`dplont df durldst prdlhshnk prdaobts. Hn pi

    ri``o` whtg tghs, ti`ontoe hnehvh

    eui`s whtg bdllorbhi` ine

    fhninbhi` mibjkrdunes nooe td

    mo roiey td ibbdlpiny tgoso

    futuro hneustry oieors is tgoy

    krdw ine lituro. Hneooe, tgo

    ovonts df =39= hn Frinbo ine

    Ourdpo sgdwoe tgit i now

    ipprdibg `hjo tghs bin mo sub

    bossfu`.

    Berhb Ldroiu

    Berhb Ldroiu

    Ehrobtdr , Goi`tgbiro

    Mryin Kirnhor & Bd

    K`dmi``y spoijhnk, Frinbo hs gd`ehnk pibo hn tgo

    hnndvithdn ribo

    [23

    HNUO]NIUHDNI@ SO]RSOBUHVOR

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    30/35

    29

    Rdurbo1 Edw Adnos Vonturo Rdurbo

    Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos1 =337=39=

    7 56

    ?3

    33

    ?3

    33

    ?3

    3Iustrhi Mo`khul Eonlirj Frinbo

    =2

    =337

    69

    2=

    ldunt df Funehnk 'L(

    Bduntry

    33

    ?3

    Korliny Notgor`ines Rpihn Rwoeon Rwhtzor ine _nhtoeJhnkedl

    6

    ?

    Loehbi` Eovhbosine Oquhplont

    ?=

    ?=

    =8??

    7=9

    ?

    =8??

    9

    5

    67

    79

    7

    59

    ;933

    23

    7==

    638=

    52

    =9

    ?2

    ;6

    =9

    93=

    8? 92;

    7=

    56

    ;2

    75

    =9

    55

    =3;

    ?;

    =6?

    989

    =

    26

    933

    ?9

    ;;

    869

    =9

    8

    9 59=2 2?92

    23

    = 8?

    92 27

    ;=5?

    ?5

    97

    5

    =?

    93

    6

    =8

    ??

    56

    ?5

    25

    92325

    87

    65

    =38

    9?9

    7?

    95=

    ?=

    62

    222

    99?

    958 95?

    96?

    =79

    33

    ?3

    Mhdpgirlibouthbi`s=338 Loehbi` Eovhbos

    ine Oquhplont

    Mhdpgirlibouthbi`s=393 Loehbi` Eovhbos

    ine Oquhplont

    Mhdpgirlibouthbi`s

    =399Loehbi` Eovhbosine Oquhplont

    Mhdpgirlibouthbi`s=39=

    Loehbi` Eovhbosine Oquhplont

    Mhdpgirlibouthbi`s

    Ibbdrehnk td tgo Edw Adnos Vonturo Rdurbo eitimiso, oquhty hnvostlonts hn VBmibjoe Ourdpoin @hfo Rbhonbosbdlpinhos erdppoe my =7/ hn =39=, frdl 9.2M hnvostoe vhi =55 eoi`s hn =399 td 8?3L hnvostoe vhi9;? eoi`s hn =39=. Ughs erdp wis erhvon my i ?3/ yoirdnyoir eob`hno hn Ourds hnvostoe hn Loehbi` Eovhbosine Oquhplont bdlpinhos. Hnvostlonts lieo hn Robdne ]dune ine @itor ]dune fhninbhnks hn Ourdpo wororo`ithvo`y stim`o, wgh`o tdti` Ourds i``dbitoe td Fhrst ]dune fhninbhnks hn =39= erdppoe ==/ bdlpiroe td=399 `ovo`s.

    Oquhty fhninbhnk df vonturofuneoe bdlpinhos virhos eristhbi``y frdl yoir td yoir hn liny bduntrhos hn Ourdpo.I`tgdukg `ovo`s df fhninbhnk hn Frinbo hn =399 ine =39= woro mo`dw tgo ?yoir ivoriko, vonturo biphti`hnvosthnk hn Frinbo bdlpiros fivdrim`y whtg Ourdpoin poor bduntrhos.

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    31/35

    2=

    IM RBHONBO

    ]ovonuo =39='J(

    @hst df pum`hb bdlpinhos hn =39=

    9 253

    ]ovonuo =399'J(

    ]&E =39='J( Olp`dyoos

    Lirjot Bip 'Ldn 9?$?$=392(

    " dfSrdeubts

    9 935 7 ;=? 68 ?;=,2 5

    BDLSINX

    IEDBHI ; 2=6 2 ;77 99 ;75 ;9 62,7 5MHDI@@HINBO SGI]LI 5 355 2 =29 8 233 ?? ;;,? 8

    MHDRXNOW 6 356 9 986 2=; =? ;,= 2BI]LIU 6 939 == 532 2; ?=7,= 9

    BO@@OBUHR =9 32= 9? 882 97 879 ==7 996,2 6EMV UOBGND@DKHOR = ;;; 9 7;2 99 ?;8 2; 995,? 2

    EOHNDVO 667 62; 2 25? 2= ?=,8 2

    EHIKNDRUHB LOEHBI@ =8 562 == ;2; 756 7= 9;,9 8ODR HLIKHNK 93 285 ; ?89 = 965 ?2 76 =

    F@ILO@ 98 8=5 =5 77? 98 82? =?3 85 6KONFHU 6 393 6 ;;7 99 295 ;6 99;,2 =

    KOND[IX 7 758 7 77; 2 5;5 n$i 7,5K@DMI@ MHDONO]KHOR 9 ;85 =75 = 8;7 27 ?9,9

    GXM]HKONHBR 5 8=; 6 ?8? = 2;? 5; 96,9 2HNNIUO SGI]LI 95 =7= 99 ;53 92 59; 79 87,2 7

    HNUOK]IKON 5 736 5 728 9 299 =6 9;,? 9HNU]IRONRO ? 962 2 ?27 9 =33 58 98,; 9

    HSRDKON$YHIKON LI]ROH@@O 92 766 93 936 2 6=2 ;5 ;3,2LI_NI JOI UOBGND@DKHOR 93 =7= ? 8;6 2 =6= ;? 92?,6 9

    LOEHIN UOBGND@DKHOR 9 3=8;5=

    = 789 5? 5;,= 9

    LOUIMD@HB OWS@D]O] = 689 9 587 7 39; 93= 6=,=NINDMHDUHW 8;3 9 263 5 29= 29 69,8 2NODVIBR 995 28= ? 538 =2 26,5 2

    NHBDW 7 26? 766 6 5;9 27 989,8 6NDVIBXU 9 93= ?38 8 =9,6 9

    RUI@@O]KONOR =?5 ;;2 =?9 926 27 633 9 933 68;,; 5

    RUONUXR = ?29 9 52= = 792 2? 937,= =UGO]IEHIK 7 ;89 93 87; 9 =33 58 96,7 ?U]INRKONO 92 369 95 556 57 6;8 =;? =72,? 6

    VOWHL = =78 = 5== 9 959 53 5;,5 =VHVI@HR ? 838 9= ??? 9= 77? 99= 9==,? =

    VHRHDLOE K]D_S 92 735 9= ?66 7= 7,2Rdurbo1 Frinbo Mhdtobg Liy =392: MhdBontury

    ` MHDI@@HINBO SGI]LI1 @drilyb, Rhtivhk` MHDLOEHBI@ UHRR_OR1 Bo``wom` BO@@OBUHR1 BinBo``, bKSR jht, EorliVix, gORBLB, ghSRGOS,UI@ONR` BD@BDL1 Eonerhehik, EonerhKrift Sd`y@yshno 'EK@(` EMV UOBGND@DKHOR1 Vhisjhn, Ehi``ortost` EHIWGDNGHU1 Ib`irusEx, UYR'Uotinus Yuhbj Rthbj(` EDRHRDFU1 OSHkriy, HRDkriy, L_=not, S@INOU DNBD` O'XO( M]IHN1 Ldmh`o OMU, LoyoINI@XRHR, LoyoSI]IEHKL S@IXO]` F@ILO@ UOBGND@DKHOR1 Loeusi, @hquhUhlo, Lhbrdpulp, Urhkkor @dbj,Eo`hVix` F@_HKONU1 LFBR, ORR`F@_DSUHBR1 F`udmoil, Inkhdstilp, RonthEyo, Inkhd`dno, F`udsthbj` KONDLHB VHRHDN1 FRGEBdlmhnk tost` K]IFUXR1 KriftysYuhbjRot, KriftysGMR ine KriftysMBS` GOLI]HNI1 Goldxbo``

    ` HLIWHD1 Rphrd`opt, Urd`dvd`` HN BO@@ I]U1 HBIFobthn, HBINthmdehos` HNNDSRXR1 HnndRbin` HNUOK]IKON1 I]HRJ` JDO@HR1 _rdstithdn` LI_NI JOI UOBGND@DKHOR1 Bo``vhshd, KistrdF`ox, Bgd`inkhdF`ox,Bgd`inkhdsbdpy, Bd`dF`ox, I`vodF`ox, IYF`ox98` LOEHIN UOBGND@DKHOR1 @LR@oshdn Linikolont Rd`uthdns` NDVIBXU1 NdviSropSrdbossdr Rystol` N_U]HI@XR LOEHBI@ N_U]HUHDN1 Bistiso, Sd`yed`` DU]21 BIBHS@HY=3, BIBHBD@=3UGO]IEHIK1 FHEHR, @HRI UribjorU]DSGDR1 S`ito ]_NNO] GE` VOWHL1 RphnoAibj` VHVI@HR1 OM66 Bo`` @hno, VHVIHRbroon

    EHIWDNGHU ? 533 ? 333 6 872 938 59,8 ;

    LOEHB]OI HNUO]NIUHDNI@ =3 ;33 9 2=6 27 65,? ==98 3??

    Y_INUO@ ?3 58= ? ;33 9;= 8,8 =7?9 366

    9; 878

    9 589

    895

    INNOW

    BDLLO]BHI@HQOE S]DE_BUR

    ;;

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    32/35

    IIMILIMBO@@MHDIENHEIEDBHIIEVINBOE MHDEORHKNIFFHBGOLIFFH@DKHBIK_OUUINU MHDUOBGI@IWHII@KONHBRI@HQO SGI]LI H OU HH

    I@QS]DUOBU RIRILI]DJ MHDUOBGND@DKHORINIBDNEI SGI]LIINIKONORHR MHDUOBGND@DKHORINHLIRBDSOINR MHDUOBGINUIKONOISUXR SGI]LIBO_UHBI@RI]BGHLLOE RI]@IU@INK]ILIU@INUHB MDNO RB]OONIWONHRIWD RBHONBO

    I

    M BO@@ EORHKNMHDI@@HINBO SGI]LIMHDI@UO]NIUHVORMHDBXUOWMHDKI@ONXRMHDKOLLIMHDLOEHBI@ UHRR_ORMHDL+_SMHDSGXUHRMHDRONUOBMHDU]HI@MHDVH]DN

    M

    E

    O'XO(M]IHNOFFHL_NOONUO]DLOO]XUOBG SGI]LIO_JI]XR

    O

    FO]LONUI@KF@ILO@ UOBGND@DKHORF@D[KONOF@_HKONUF@_DFI]LIF@_DSUHBRFDKI@O NINDUOBG

    F

    KI@ONHW HNNDVIUHDNRKONDLHB VHRHDNKONDRIFO RIRKONDRB]OONKONUHBO@K@DMI@ MHDONO]KHORK@XBDEOK@XBDEHIKK]IFUXRKUS UOBGND@DKX

    K

    JI@XBO@@JO@HIJODRXRJGD]HDNXWJDO@HRJD[DJ UGO]IKNDRUHB

    J

    @IMD]IUDH]O RXLMHDUOB@UJFI]LI@_NKHNNDV

    @

    LIN]DR UGO]ISO_UHBRLI_NI JOI UOBGND@DKHORLOEHIN UOBGND@DKHORLOEHU RILOERONHBLOHDKONHWLO@@HUOBGLOUIMD@HB OWS@D]O]LOUIM]IHN ]OROI]BGLOUHR MHDUOBGND@DKHORLHNLIWLOEHBI@

    L

    NINDMHDUHW R.I.NINDLOERXNNIUONBISRNIU_]I@SGINIU_]ILD@ONODVIBRNO_]DNIWNHBDWNDJIENDRDSGI]LNDVIBXUNDVIEHRBDVO]XNDVDUOBN_U]HI@XR LOEHBI@N_U]HUHDN

    N

    S@_KLOE GOI]USD@XS@_R U]INRFOBUHDNSDWO@S]ORMOIRXS]HLIEHIKS]DUNOUODLHWS]DVONBO UOBGND@DKHOR RIRSW+UGO]ISO_UHBR

    BI]@HNI UOBGND@DKHORBI]LIU RIBIX@IHNVHVDKONBO@ONXRBO@@OBUHRBO]ONHR UGO]ISO_UHBRBH@DIBD@BDLBDNHEHIB]DRRAOBUBXMO]NINDBXUGO]HRBXUDD BO@@ I]BGHUOBUR

    BXUDRHI@ MHDLOEHB

    B

    EI VD@UO]]IEMV UOBGND@DKHOREOHNDVOEONE]HREONE]HUHBREHIFH]EHI@SGIEHIWGDNHUENI UGO]ISO_UHBREDLIHN UGO]ISO_UHBREDRHRDFU

    GOLI]HNIGHRUI@HLGD]_R SGI]LIGXM]HKONHBR

    G

    Y_INU_L KONDLHBRY

    ]MNIND]EMHDUOBG]NUOBG F]INBO]DDU @HNOR UOBGND@DKX

    ]

    RBINO@HRRB]OONBO@@RO@OWO@RONRD]HDNRHRONORJ_@EUOBGRS@HBDR

    RUOLBHRR_]KHVHRHDRXNISBO@@ RIRRXNS]DRHR

    R

    UI]KODNUMF, KONHO UHRR_@IH]OUGO]IB@HDNUGO]IEHIKUGO]IVOBUXRU]INRKONOU]DSGDRUWBO@@

    U

    HEMHDHELXJHLIWHDHLL_UOSHN BO@@ I]UHNEHBHI MHDUOBGND@DKXHNNIUO SGI]LIHNNDMHDBGHSRHNNDSRXRHNNDVIUHVO GOI@UG EHIKNDRUHBRHNUOK]IKON RIHNVOBUXR

    H

    DNBDEORHKNDNBDLOEHBRD]HMIRO SGI]LIDU]2

    D

    SGI]LI@OIERSGI]NOWUSGO]OBXEOR SGI]LISGX@DKONOSGXRHJ]DNSGXRHDRUHLSHBDU[HRUSH@DRBHONBORS@INU IEVINBOEUOBGND@DKHOR SIU

    S

    VIWDN MHDUOBGVOWHL RIVH]DWHRVHUILFO]DVHVI@HRVDWBIN

    V

    [HUUXBO@@

    [

    WONUOBG

    W

    Now pirthbhpints

    @HRU DF 976 BDLSINHOR SI]UHBHSIUHNK HN UGO RU_EX

    22

    http://www.aabam.com/http://abcell-bio.com/http://www.adnid.fr/http://www.adocia.com/http://www.a-biodesign.com/tag/advanced-biodesignhttp://www.affichem.fr/http://www.affilogic.com/http://www.aguettant.com/http://www.alaxia-pharma.eu/http://www.algenics.fr/http://www.alz-pharma.com/http://www.alzprotect.com/http://www.amarokbiotech.com/http://www.anacondapharma.com/http://www.animascope.eu/http://www.ans-biotech.com/http://www.antagene.com/http://aptys-pharmaceuticals.com/http://www.archimmed.com/http://www.atlangram.com/http://www.atlantic-bone-screen.com/FR/http://www.pasteur.fr/ip/easysite/pasteur/fr/relations-industrielles/start-uphttp://www.axoscience.com/http://www.b-cell-design.com/http://www.bioalliancepharma.com/http://www.bioalternatives.com/http://www.biocytex.fr/http://www.biogalenys.com/http://www.biogemma.com/http://www.biometiss.com/http://www.biomup.com/http://www.biophytis.com/http://www.biosentec.fr/http://www.biotrial.com/http://www.bioviron.fr/http://www.eye-brain.com/ebrainv5/index.php?lang=enhttp://www.effimune.com/http://www.enterome.com/http://www.erytech.com/http://www.eukarys.com/http://www.fermentalg.com/http://www.flamel.com/http://www.flowgene.com/http://www.fluigent.com/http://www.fluofarma.com/http://www.fluoptics.com/http://www.fogalebiotech.com/http://www.galenix.fr/http://www.genomicvision.com/http://www.genosafe.com/http://www.genoscreen.com/http://www.genticel.com/http://www.global-bioenergies.com/index.php?lang=frhttp://www.glycode.fr/http://www.glycodiag.com/http://www.graftys.com/http://www.gtptech.com/http://www.kaly-cell.com/http://www.kelia-pharma.com/http://www.keosys.com/http://www.khorionyx.com/http://www.koelis.com/http://www.kowok-theragnostic.com/http://www.symbiotec.fr/http://www.ltkfarma.com/http://www.lunginnov.com/http://www.manros-therapeutics.com/en/http://www.maunakeatech.com/http://www.mediantechnologies.com/http://www.medit.fr/http://www.medsenic.com/http://www.meiogenix.com/http://www.mellitech.com/http://www.metabolic-explorer.com/http://www.metabrainresearch.com/http://www.metis-biotech.com/http://www.minmaxmedical.com/http://www.nanobiotix.com/http://www.transferts-lr.org/transferts_lr/recherche_publique_en_region/actualites/partenariats_entreprises_recherche/nanomedsyn_une_start_up_dans_le_domaine_de_la_sante_creee_a_l_ibmm_institut_des_biomolecules_max_mousseronhttp://www.premice-bourgogne.com/fichiers/contenu_fichiers1/1080/Yves%20WACHE.pdfhttp://www.naturalpha.com/http://www.naturamole.com/http://www.neovacs.com/http://www.neuronax.com/http://www.nicox.com/http://www.nokad-pharma.com/http://www.nosopharm.com/http://www.novacyt.com/http://www.novadiscovery.fr/http://www.novotec-labs.com/http://www.nutrialys.fr/http://www.nutrialys.fr/http://www.plugmed.com/http://www.polyplus-transfection.com/http://www.poxel.com/http://www.crealys.com/portfolio_item/presbeasy/http://www.primadiag.com/http://www.protneteomix.com/http://www.provetech.com/http://www.px-therapeutics.com/http://www.carlinatech.com/http://www.carmatsa.com/http://www.invivogen.com/http://www.celenys.com/http://www.cellectis.com/http://www.cerenis.com/http://www.ciloa.fr/http://www.colcom.eu/http://www.conidia.fr/http://www.crossject.com/http://www.cybernano.eu/http://www.cytheris.com/http://www.cytoo.com/http://www.cytosial.com/http://www.davolterra.com/http://www.dbv-technologies.com/http://www.deinove.com/http://www.dendris.fr/http://www.dendritics.net/http://www.diafir.com/http://www.dialpha.com/http://www.diaxonhit.com/http://www.dna-therapeutics.com/http://www.domaintherapeutics.com/http://www.dosisoft.com/http://www.hemarina.com/http://www.histalim.com/http://www.horus-pharma.com/http://www.hybrigenics.com/http://www.quantum-genomics.com/http://www.rbnano.fr/http://www.rd-biotech.com/http://www.rntech.com/http://www.rootlines-tech.com/http://www.scanelis.com/http://www.screencell.com/http://www.selexel.com/http://www.sensorion-pharma.com/http://www.sisene.com/http://www.skuldtech.com/http://www.splicos.com/http://www.stemcis.com/http://www.surgivisio.com/http://www.synapcell.com/http://www.synprosis.com/http://www.tbf-lab.com/index.htmlhttp://www.theraclion.com/http://www.theradiag.com/http://www.theravectys.com/http://www.transgene.fr/http://www.trophos.com/http://www.txcell.com/http://www.idbio.eu/http://www.idmyk.com/http://www.imaxio.com/http://www.immutep.com/http://www.incellart.com/http://www.indicia.fr/http://www.innate-pharma.com/http://www.innobiochips.fr/http://www.innopsys.com/http://www.ihdiag.com/http://www.integragen.com/http://www.invectys.com/http://www.oncodesign.fr/http://www.oncomedics.com/http://www.oribase-pharma.com/http://www.otr3.com/http://www.pharmaleads.com/http://www.pharnext.com/http://fr.pherecydes-pharma.com/http://www.phylogene.com/http://www.physikron.com/http://www.physiostim.com/http://www.picotwist.com/http://www.pilosciences.com/http://www.plantadvanced.com/http://www.plantadvanced.com/http://www.vaxon-biotech.com/http://www.vexim.com/http://www.viroxis.com/http://www.vitamfero.com/http://www.vivalis.com/http://www.voxcan.fr/http://www.wittycell.com/http://www.xentech.eu/http://abcell-bio.com/http://www.xentech.eu/http://www.wittycell.com/http://www.voxcan.fr/http://www.vivalis.com/http://www.vitamfero.com/http://www.viroxis.com/http://www.vexim.com/http://www.vaxon-biotech.com/http://www.txcell.com/http://www.trophos.com/http://www.transgene.fr/http://www.theravectys.com/http://www.theradiag.com/http://www.theraclion.com/http://www.tbf-lab.com/index.htmlhttp://www.synprosis.com/http://www.synapcell.com/http://www.surgivisio.com/http://www.stemcis.com/http://www.splicos.com/http://www.skuldtech.com/http://www.sisene.com/http://www.sensorion-pharma.com/http://www.selexel.com/http://www.screencell.com/http://www.scanelis.com/http://www.rootlines-tech.com/http://www.rntech.com/http://www.rd-biotech.com/http://www.rbnano.fr/http://www.quantum-genomics.com/http://www.px-therapeutics.com/http://www.provetech.com/http://www.protneteomix.com/http://www.primadiag.com/http://www.crealys.com/portfolio_item/presbeasy/http://www.poxel.com/http://www.polyplus-transfection.com/http://www.plugmed.com/http://www.plantadvanced.com/http://www.pilosciences.com/http://www.picotwist.com/http://www.physiostim.com/http://www.physikron.com/http://www.phylogene.com/http://fr.pherecydes-pharma.com/http://www.pharnext.com/http://www.pharmaleads.com/http://www.otr3.com/http://www.oribase-pharma.com/http://www.oncomedics.com/http://www.oncodesign.fr/http://www.nutrialys.fr/http://www.novotec-labs.com/http://www.novadiscovery.fr/http://www.novacyt.com/http://www.nosopharm.com/http://www.nokad-pharma.com/http://www.nicox.com/http://www.neuronax.com/http://www.neovacs.com/http://www.naturamole.com/http://www.naturalpha.com/http://www.premice-bourgogne.com/fichiers/contenu_fichiers1/1080/Yves%20WACHE.pdfhttp://www.transferts-lr.org/transferts_lr/recherche_publique_en_region/actualites/partenariats_entreprises_recherche/nanomedsyn_une_start_up_dans_le_domaine_de_la_sante_creee_a_l_ibmm_institut_des_biomolecules_max_mousseronhttp://www.nanobiotix.com/http://www.minmaxmedical.com/http://www.metis-biotech.com/http://www.metabrainresearch.com/http://www.metabolic-explorer.com/http://www.mellitech.com/http://www.meiogenix.com/http://www.medsenic.com/http://www.medit.fr/http://www.mediantechnologies.com/http://www.maunakeatech.com/http://www.manros-therapeutics.com/en/http://www.lunginnov.com/http://www.ltkfarma.com/http://www.symbiotec.fr/http://www.kowok-theragnostic.com/http://www.koelis.com/http://www.khorionyx.com/http://www.keosys.com/http://www.kelia-pharma.com/http://www.kaly-cell.com/http://www.invectys.com/http://www.integragen.com/http://www.ihdiag.com/http://www.innopsys.com/http://www.innobiochips.fr/http://www.innate-pharma.com/http://www.indicia.fr/http://www.incellart.com/http://www.immutep.com/http://www.imaxio.com/http://www.idmyk.com/http://www.idbio.eu/http://www.hybrigenics.com/http://www.horus-pharma.com/http://www.histalim.com/http://www.hemarina.com/http://www.gtptech.com/http://www.graftys.com/http://www.glycodiag.com/http://www.glycode.fr/http://www.global-bioenergies.com/index.php?lang=frhttp://www.genticel.com/http://www.genoscreen.com/http://www.genosafe.com/http://www.genomicvision.com/http://www.galenix.fr/http://www.fogalebiotech.com/http://www.fluoptics.com/http://www.fluofarma.com/http://www.fluigent.com/http://www.flowgene.com/http://www.flamel.com/http://www.fermentalg.com/http://www.eukarys.com/http://www.erytech.com/http://www.enterome.com/http://www.effimune.com/http://www.eye-brain.com/ebrainv5/index.php?lang=enhttp://www.dosisoft.com/http://www.domaintherapeutics.com/http://www.dna-therapeutics.com/http://www.diaxonhit.com/http://www.dialpha.com/http://www.diafir.com/http://www.dendritics.net/http://www.dendris.fr/http://www.deinove.com/http://www.dbv-technologies.com/http://www.davolterra.com/http://www.cytosial.com/http://www.cytoo.com/http://www.cytheris.com/http://www.cybernano.eu/http://www.crossject.com/http://www.conidia.fr/http://www.colcom.eu/http://www.ciloa.fr/http://www.cerenis.com/http://www.cellectis.com/http://www.celenys.com/http://www.invivogen.com/http://www.carmatsa.com/http://www.carlinatech.com/http://www.bioviron.fr/http://www.biotrial.com/http://www.biosentec.fr/http://www.biophytis.com/http://www.biomup.com/http://www.biometiss.com/http://www.biogemma.com/http://www.biogalenys.com/http://www.biocytex.fr/http://www.bioalternatives.com/http://www.bioalliancepharma.com/http://www.b-cell-design.com/http://www.axoscience.com/http://www.pasteur.fr/ip/easysite/pasteur/fr/relations-industrielles/start-uphttp://www.atlantic-bone-screen.com/FR/http://www.atlangram.com/http://www.archimmed.com/http://aptys-pharmaceuticals.com/http://www.antagene.com/http://www.ans-biotech.com/http://www.animascope.eu/http://www.anacondapharma.com/http://www.amarokbiotech.com/http://www.alzprotect.com/http://www.alz-pharma.com/http://www.algenics.fr/http://www.alaxia-pharma.eu/http://www.aguettant.com/http://www.affilogic.com/http://www.affichem.fr/http://www.a-biodesign.com/tag/advanced-biodesignhttp://www.adocia.com/http://www.adnid.fr/http://www.aabam.com/
  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    33/35

    25

    Oxghmht Hneox

    9

    =

    2

    5

    ?

    6

    ;

    7

    8

    93

    99

    9=

    92

    95

    9?

    96

    9;

    97

    98

    =3

    =9

    ==

    =2

    Ovd`uthdn df @hfo Rbhonbos Bdlpiny Broithdn hn Frinbo 3;

    Nulmor df olp`dyoos 93

    @ovo` df Oeubithdn Ibghovoe my Olp`dyoos 93

    Bdlpinhos my iko 99

    Drhkhn df tgo bdlpiny 99

    Edlihn df Ibthvhty 99

    Bdlpinhos broitoe dr `hquheitoe hn =39= 9=

    Ehstrhmuthdn df Sirtnorsghp Uypos 95

    Ehstrhmuthdn df B`honts my Hneustry Robtdr 95

    Sitont Ipp`hbithdns 96

    Sitonts ]obohvoe 96

    Sitonts Oxp`dhtoe 96

    Ugoripouthb Srdeubts my Fdbus Iroi 97

    Ugoripouthb Srdeubts my Rtiko df Eovo`dplont 97

    Ehikndsthb Srdeubts my Fdbus Iroi 98

    Ovd`uthdn df @hfo Rbhonbos Hneustry Funehnk =3

    Ovd`uthdn df Fronbg @hfo Rbhonbos HSDs dn NXRO Ourdnoxt =3

    Ehstrhmuthdn df VB Funehnk =9

    Xdunk Hnndvithvo Ontorprhso Rtitus 'AOH( ==

    @hfo Rbhonbos HSD Funerihshnk my Bduntr y1 NXRO Ourdnoxt ine I`tornoxt =6

    Lirjot Biphti`hzithdns my Bduntry1 NXRO Ourdnoxt ine I`tornoxt Mhdtobgnd`dky

    ine Loehbi` Oquhplont Bdlpinhos =6

    NXRO NOWU Mhdtobg Hneox =;

    Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos1 =337=39= =8

  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    34/35

    BroehtsSgdtds 1 Fdtd`hiIrthsthb Ehrobthdn 1 S`us quo `os ldts

    Imdut Frinbo MhdtobgFrinbo Mhdtobg hs tgo issdbhithdn df Fronbg bdlpinhos hn tgo @hfo Rbhonbos sobtdr inetgohr pirtnors. Hts lhsshdn hs td bdntrhmuto td edlosthb krdwtg hn tghs hnndvithvo hneustryine td suppdrt Frinbos `oieorsghp rd`o whtghn tgo Ourdpoin @hfo Rbhonbos bdllunhty.Ldro spobhfhbi``y, Frinbo Mhdtobg ibts is in onkhno df bginko my hntoribthnk whtg tgokdvornlont, obdndlhb drkinhzithdns, ibieolhb hnsthtuthdns, tgo loehi ine tgo hnvostdrbdllunhty td onsuro tgo prhdrhthzithdn df tgo @hfo Rbhonbos sobtdr hn Frinbo ine tgohlprdvolont df tgo obdndlhb, `oki`, roku`itdry ine linikorhi` onvhrdnlonts fdr tghshlpdrtint hneustry.

    Broitoe hn 988;, Frinbo Mhdtobg unhtos tgo oieors df hnndvithvo @hfo Rbhonbos bdlpinhoswhtg tgohr pirtnors hn tgo hnvostlont, `oki` ine ibieolhb fho`es. Lolmors bdlo frdl i``dvor Frinbo ine roprosont oibg fho`e df tgo @hfo Rbhonbos 'mhdtobgnd`dky, loehbi` tobgnd`dky, b`oin$kroon tobgnd`dky(. _neor tgo minnor df Frinbo Mhdtobg, tgoso hneustry`oieors fhkgt td broito i now ldeo` df ontropronoursghp hn Frinbo ine td suppdrt tgobroithdn df bdlpinhos ine adms hn tghs hnndvithvo sobtdr. @oe my Iner Bgdu`hji shnbo=338, Frinbo Mhdtobg bdnthnuos td sd`hbht pum`hb pdwors, obdndlhb eobhshdn lijors inetgo loehi dn mogi`f df ibtdrs hn tgo Fronbg @hfo Rbhonbos.

    Sindrili RtueyRhnbo =33=, Frinbo Mhdtobg gis bdneubtoe tgo Sindrili df tgo @hfo Rbhonbos Hneustryhn Frinbo, i unhquo stuey tgit prdvheos in innui` upeito dn tgo krdwtg ine eynilhsldf tghs hnndvithvo sobtdr hn Frinbo. Ugo rosu`ts df tghs stuey i``dw Frinbo Mhdtobg td krdune

    hts prdpdsi`s td tgo kdvornlont hn gire fibts ine td offobthvo`y roprosont tgo onthrohneustry. Ugo Sindrili ini`ysos eiti frdl hneoponeont bdlpinhos i``dbithnk it `oist9?/ df tdti` sponehnk td ]osoirbg ine Eovo`dplont bdsts. Frinbo Mhdtobg survoyoeldro tgin 533 bdlpinhos vhi i soburo dn`hno quosthdnnihro ine gis ini`yzoe tgo eitiprdvheoe frdl 976 df tgo 98= tdti` rospdnsos. Ugo rosu`ts df tghs sur voy wh`` rolihn tgoprdporty df Frinbo Mhdtobg.

    Giueo Bdsti

    Konori` RobrotiryFrinbo Mhdtobg

    Mondt Mrdbire

    Srdaobt LinikorFrinbo Mhdtobg

    Edlhnhquo ]onburo`

    SirtnorDrjds Biphti`

    Vhrkhnho Fdntihno

    Hnndvithdn OxportDROD

    Sh`dt Bdllhttoo

    Berhb Kuh``orlo

    Srdaobt @oieor,Mhdtobgnd`dkyEKBHR

    Bgigri @duifh

    Hnvostlont Ehrobtdrit BEB Ontroprhsos

    Shorro Rdr`hor

    Srdaobt @oieor,Lhnhstry fdrHneustrhi` ]onowi`EKBHR

    Ehsb`ihlor

    I`tgdukg dur most offdrts woro khvon td issurhnk tgo ibburiby inebdlp`otonoss df tgo hnfdrlithdn prdvheoe hn tghs ropdrt, ht hs pdsshm`otgit bortihn eotih`s givo osbipoe dur ndthbo. S`oiso shkni` iny orrdrsdr dlhsshdns my olih`hnkbdntibtCfrinbomhdtobg.drk

    http://localhost/var/www/apps/conversion/tmp/scratch_3/[email protected]://localhost/var/www/apps/conversion/tmp/scratch_3/[email protected]
  • 7/23/2019 Etude 2012-VInteractive FranceBiotech

    35/35

    Frinbo Mhdtobg2$? H ] h``